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The bioavailability of hydrophobic drugs is critically dependent on the development of efﬁcient and safe
drug delivery vehicles. Nanoparticulate pharmaceutical carriers commonly used in delivery of active
components are often non-ionic in nature. Among them polyether based amphiphiles have become
increasingly relevant over the past decades. Polyether based amphiphiles exhibit good chemical stability,
high water solubility, low toxicity, have decreased interaction with blood components, and are highly
biocompatible; and thus have been applied in biomedical and pharmaceutical areas. The current review
highlights the synthetic progression and biomedical applications of these non-ionic polyether-based
amphiphilic architectures, some unresolved issues and challenges, along with the future perspective of
polyether based nanocarriers for delivery of active components.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Today, the major problems with the vast majority of clinically
used drugs are their short half-life in the bloodstream and high
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-NC-ND license.market are small molecules; these drugs typically interact through
multiple binding sites and diffuse rapidly all over the body without
selectivity. As a consequence, a relatively small amount of the drug
reaches the target site, while the non-selective distribution in the
body leads to undesired side effects. The applied dose of the drug is
reduced to avoid these side effects, thus the full therapeutic
potential of the drug is not achieved. These disadvantages are
especially pronouncedwith drugs that exhibit a narrow therapeutic
index [1] such as anti-cancer, anti-rheumatic, and immunosup-
pressive agents. Improving the therapeutic index of drugs is a major
incentive for innovation in many therapeutic areas and the search
for new drug-delivery concepts and new modes of action are the
major driving force in polymer therapeutics [2e5]. Furthermore,
many of the drugs are hydrophobic and have limited aqueous
solubility. The current approach towards drug delivery also aims at
solubility enhancement of poorly water soluble drugs. Clinically
acceptable organic solvents, Cremophor EL, and certain surfactants
are used in formulations for solubility enhancement [6]. However,
they have certain shortcomings such as toxicity, undesirable side
effects [7], and hypersensitivity reactions [8e11]. To address such
toxicity issues as well as to extend the systemic circulation time of
the lipoplexes, polymeric architectures may provide a solution
because of their resemblance to natural carriers like viruses and
serum lipoproteins [12].
Over the last few decades, research on nanoscale drug delivery
vehicles has been largely concerned with an outright development
of modern pharmaceutical technology. Polymeric nanoparticles are
particularly interesting for drug delivery applications because of
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penetrate smaller capillaries and be taken up by cells, which allows
an efﬁcient drug accumulation at the target sites. Also, biode-
gradable materials can be used in nanoparticle preparation, which
allows sustained drug release within the target site over an
extended period of time. Drug loaded polymeric nanocarriers
passively accumulate in the large gaps between the adjacent
endothelial cells in the tumor neovasculature, while the poor
lymphatic drainage leads to enhanced retention of these macro-
molecules within the tumors and enhances the drug delivery in the
tumors sites [13,14] via a phenomenon termed “enhanced perme-
ability and retention “(EPR)” by Maeda and Matsumura [15,16]. So
far, a number of macromolecular delivery systems are under
investigation to bypass these boundaries and expand the
prospective of the respective drug. Many different drug delivery
vehicles such as block copolymer micelles [17], polymer grafted
liposomes [18] or dendritic core-shell type architectures [19] have
been realized in recent years.
Among the many nanoparticulate pharmaceutical carriers being
studied for the delivery of extremely hydrophobic drugs, amphi-
philic architectures are of particular interest and have signiﬁcantly
affected the drug delivery era. These amphiphilic nanocarriers can
be ionic or non-ionic. Ionic amphiphiles, particularly the cationic
one, have been developed as promising carriers for genetic mate-
rials and receptor targeted gene therapy [20,21]. Although cationic
amphiphiles suffer from certain limitations, such as excess positive
charge of the lipoplexes favor non-speciﬁc electrostatic interactions
with negatively charged hydrophobic serum albuminate proteins,
cellular components such as low density lipoproteins and macro-
globulines, and myriads of other negatively charged systemic
molecules [22e24]. Such non-speciﬁc interactions promote
a promiscuous binding of the transfection complexes to biological
surfaces and other systemic molecules at the cost of compromised
targeted lipofection [21]. In order to address the previous concerns
in addition to toxicity issues associated with the cationic amphi-
philes, the search for alternative architectures for targeted drug
delivery has brought non-ionic amphiphilic architectures into the
lime light. Their advantages over ionic amphiphiles include their
pH independence and the generation of non-toxic nanoparticulate
aggregates, which provide a great beneﬁt for drug delivery.
The research in the ﬁeld of non-ionic amphiphiles is growing
rapidly and the applications include solubility enhancement for
nanodevices [25e28], template synthesis [29e31], and delivery of
various drugs [32e35] including low molecular weight anti-cancer
drugs, contrast/imaging agents, proteins, plasmid DNA etc.
[36e40]. Polyether based non-ionic self-assembled architectures
have attracted considerable attention due to their resemblance
with natural carriers. Advances have been made from conventional
amphiphiles to Pluronics (triblock PEO-PPO-PEO copolymers),
PEGylated amphiphiles to dendritic structures, and hyperbranched
amphiphilic polymers to core multi-shell architectures. These
special architectures of amphiphilic molecules can result in
aggregate morphologies at interfaces and different self-assembly
behavior in solutions. Currently, several promising candidates are
in clinical trials and have paved the way towards the development
of nano-DDS [36].
Polyether based hydrophilic polymers have been extensively
used to enhance the pharmacokinetic properties of drug carriers
because of their high biocompatibility. PEG is considered as a gold
standard in the ﬁeld of drug delivery and has FDA approval for
different drugs. Due to its speciﬁc properties, such as water solu-
bility, non-toxicity, ion-transporting ability, decreased interaction
with blood components, high chemical stability, and biocompati-
bility, it has found potential applications in biomedical and phar-
maceutical areas [41,42]. As a potential alternative to PEG e.g.poly(glycerols) [41] and aliphatic dendritic polyethers, polyols,
which have a biocompatible polyether scaffold, high-end group
functionality, and a compact, well-deﬁned dendrimer-like archi-
tecture, have also become important. These characteristics of
dendritic polyether scaffolds are been currently used to generate
new material properties for biomedical applications. Such mate-
rials have the potential to create extremely high local concentra-
tions of drugs, molecular labels, or probe moieties and to modulate
therapeutic efﬁcacy of the active molecules [43].
Considering the importance of non-ionic amphiphiles in drug
delivery and taking into account the numerous useful properties of
polyether based scaffolds, our focus here will be on the polyether
based non-ionic amphiphiles, in particular, the recent synthetic
progression in the development of amphiphilic nanocarriers from
PEG based block copolymers, to PEGylated comb-like architectures,
and to dendritic, hyperbranched and core multi-shell architectures
along with their biomedical applications. The conceptual progres-
sion has occurred taking into account the drawbacks of linear
polymers and to improve upon the nanocarrier architecture for
drug delivery. Although, linear PEG based polymers have been
successfully implicated for the delivery of bioactive components
through the systemic circulation, still they have certain limitations,
such as dissociation under high dilution conditions and thus lack of
long term stability, accumulation in the body above an uncertain
excretion limit and immunological responses. Advanced polymeric
materials such as dendritic, hyperbranched and core multi-shell
architectures have now been introduced, which avoid the problems
of dissociation and are stable in high dilution conditions, have
reproducible pharmacokinetic behavior, and are now being evalu-
ated for their safety and ability to deliver therapeutic agents
[44,45]. The synthetic progression of these non-ionic polyether-
based amphiphiles (Fig. 1) will be discussed in this review.
2. Non-ionic amphiphilic nanocarriers based on PEG
A number of macromolecular delivery systems are under
investigation to bypass the boundaries of clinical drugs and expand
the prospective of the respective drug. Further, a high solubilizing
capacity and a good physical stability are two critical factors for
ideal drug delivery systems, which can be achieved by micelles
possessing several characteristics, such as low CMC, suitable size of
100e200 nm, sufﬁcient half-life in the body, non-toxic degraded
components, and ease of excretion [46,47]. PEG based ABCs have
gained a worldwide interest as one of the versatile classes of
biomaterials in DDS [46]. PEG is most commonly used as the
hydrophilic segment of these copolymers, because of its unique
physicochemical characteristics (high water solubility, high ﬂexi-
bility, and large exclusion volume) provide good “stealth” proper-
ties [48e50]. PEG’s hydrophilic surface allows prolonged
circulation of polymeric micelles in the bloodstream. This is
because the hydrophilic shell of PEG acts as a dense brush of highly
hydrated chains that rapidly sweep out a large exclusion volume.
The barrier formed by the PEG chains around the hydrophobic core
of the micelle serves to minimize interactions with proteins,
enzymes, and cells [51] and provides the stability to micelles.
Furthermore, the micelles of ABCs have a remarkably low CMC
(105e107 M) as compared to that of surfactant molecules, and
their slow kinetic dissociation makes them more suitable for drug
delivery [38].
2.1. Block copolymeric amphiphiles and Pluronics
The medicinal applications of ABCs has been well recognized,
one of the widely researched area is to use them as pharmaceutical
carriers in drug delivery. Herein our focus is on studying the self-
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Fig. 1. Synthetic progression of non-ionic polyether based amphiphilic architectures.
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the solubility of hydrophobic drugs for drug delivery. Although
many other methods such as adjustment in pH, cosolvents, cyclo-
dextrins, surfactants, etc. have been used to improve the water
solubility of drugs, each of them has their inherited problems and is
unable to achieve an adequate drug dose for therapy [52]. In order
to overcome these limitations and to enhance the water solubility
of drugs, studies have largely been conﬁned to two different areas.
One utilizes the development of ABCs in which the drug is physi-
cally adsorbed or entrapped within an insoluble polymer matrix,
the second includes soluble prodrugs or drug carriers where the
drug is either chemically bound to the backbone of block copolymer
or is part of the backbone itself [53,54]. A large variety of such
copolymers have been studied: dexamethasone (DEX) conjugated
to poly(aspartate) block of PEG-p(Asp) copolymer using hydrazine,
ester, and hydrazine-ester dual linker [55]; paclitaxel (PTX)
conjugated to PEG-poly(aspartate-hydrazide) with the aid of 4-
acetyl benzoic acid (4AB) and with levulinic acid (LEV) dual linkerto achieve PEG-p(Asp-Hyd-4AB-PTX) and PEG-p(Asp-Hyd-LEV-
PTX) [56]; doxorubicin (DOX) conjugated to poly(caprolactone)
unit of PEG-PCL copolymer via hydrazine linker [57] and poly(-
aspartic acid) with chemically conjugated DOX (pAsp(DOX)) [58].
These systems have also been tested for drug release at different pH
due to acid cleavable linkages used for drug conjugation. There are
more such examples e.g. poly(propylene) glycol (PPO Pluronics)
[59], PEG-poly(b-benzyl-L-aspartate) (PBLA) [60] and poly(ester)s
such as PEG-poly(lactic acid) (PLA) [61,62], and PEG-PCL [63,64]
that have been widely used for physical entrapment of drugs.
Currently, several such examples have progressed into clinical
trials, e.g., [DOX-encapsulated PEGe(PPO)ePEG] micelle (SP1049C)
in phase III [36], [PTX-encapsulated PEGep(Asp) block copolymer]
micelle (NK105) in phase II [65,66], [PTX-encapsulated PEGePLA
block copolymer] micelle (Genexol-PM) in phase II [67], [SN-38
(the active form of irinotecan hydrochloride) encapsulated
PEGepoly(glutamate)block copolymer] micelle (NK012) in phase II
[36,68,69], and cisplatin-incorporated PEGepoly(glutamate) block
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recently by Kataoka et al. [36].
Pluronics block copolymers have also been widely studied for
drug solubilization. Pluronics, i.e., (PEOn-PPOm-PEOn) is an
amphiphilic copolymer whose hydrophilicity (PEO unit) and
hydrophobicity (PPO unit) can be varied by changes in the molec-
ular weight of its units. The use of pluronic micelles in drug delivery
has been extensively reviewed by Kabanov et al. [71,72]. Mei et al.
reported a docetaxel loaded PCL-pluronic F68 system which gives
200 nm spherical shape nanoparticles. The cytotoxicity of these
particles was found to be comparative to commercial Taxotere in
the MCF-7 TAX30 cell line [73]. Sun et al. coupled stearic acid (SA)
to a free hydroxyl group of PEO blocks of pluronic F127 which
lowers the CMC of pluronic F127 and provides more stable micelles
which were used for DOX encapsulation. This formulation
enhanced in vitro cytotoxicity against MCF-7 cell lines as compared
to free DOX [74]. Physical mixing of two types of pluronics L81 and
P123 has also been done to produce more stable micelles by
lowering the CMC which showed high solubilization potential for
hydrophobic drugs [75].
PLA is a synthetic biodegradable polymer, thus PEG-PLA copol-
ymers have beenwidely used in drug delivery. The recent advances
of these copolymers have been reviewed by Zeng et al. [76]. These
studies have proven the practical utility of polymer self-assemblies
as injectable nano-drug delivery systems through both experi-
mental and clinical results, which has generated much interest
because they provide a strong foundation for further development
in the nano-DDS ﬁeld. There has also been progress in improving
the pharmacokinetics and pharmacodynamics of existing drugs.
Lang et al. majorly contributed to (PEG-b-PCL)-based amphiphilic
block copolymers for achieving a better micellar drug delivery
system with improved solubilization and delivery of DOX with
thermo and pH responsive release mechanisms [77e79]. The high
loading efﬁciency and in vivo stability of PTX was achieved with
hydrolytic block copolymer micelles of PEG-poly(4-(2-
vinylbenzyloxy-N-picolylnicotinamide)), i.e., PEG-p(VBOPNA) [80]
and PEG-poly(2-(4-vinylbenzyloxy)-N,N-diethylnicotinamide), i.e.,
PEG-p(VBODENA) [81]. The more relevant results for improving the
loading efﬁciency of drugs are summarized by Cheng et al. [82].
Recently, Gao et al. synthesized multifunctional polymeric
micelles that incorporate therapeutic agents, molecular targeting,
and diagnostic imaging capabilities to improve the therapeutic
outcome of drug therapy [74]. This was achieved by amphiphilicScheme 1. Synthesis of amphblock copolymers of maleimide-terminated PEG-b-poly(D,L-lactide)
(MAL-PEG-PLA), and methoxy-terminated PEG-b-poly(D,L-lactide)
copolymer (MPEGPLA). The targeting ligand, i.e, RGD was attached
to the micelle surface through a covalent thiol-maleimide linkage
(0e16)%. Thesemicelles were used to incorporate DOX and a cluster
of super paramagnetic iron oxide (SPIO) nanoparticles inside the
micelle core by a solvent-evaporation method at 6.7 and 2.7 w/w%,
respectively. This system enables the selective targeting as well as
detection of micelles at nanomolar concentration and an active pH-
triggered release of encapsulated DOX. Lavasanifar et al. reported
a DOX delivery system based on DOX-conjugated (PEO-b-PCL) block
copolymers and also PEO-b-PCL micelles bearing benzyl, carboxyl,
or DOX groups in the core for the physical encapsulation of DOX,
where a maximum level of drug-loading and control over the rate
of DOX release was achieved by polymeric micelles containing
benzyl groups in the core [83]. These ABCs were also successfully
demonstrated for active cancer targeting by using tri-peptide RGD
ligand conjugated to PEO-b-PCL copolymers [57].
More details on ABCs in drug delivery, such as engineering of
micelle core and shell to achieve stable micelles with high loading
capacity and control over drug release along with active targeting,
are summarized by Lavasanifar et al. in a recent review article [84].
2.2. Comb-like polymeric amphiphiles
Watterson et al. generated amphiphilic PEGylated block copol-
ymers by polymerizing dimethyl isophthalates, having alkoxy
group at the C-5 position with the PEG diol in the presence of
organometallic catalyst (Scheme 1) [85]. This methodology
required harsh reaction conditions and the quality of synthesized
amphiphiles was not very suitable for biomedical studies due to
metallic contamination. In order to overcome these limitations,
they developed a greener chemo-enzymatic approach to carry
condensation polymerization of dimethyl-5-hydroxy-isophthalate
with PEG diol (Mn 600e1500 Da). Polymerization occurred in
a chemo-selective manner leaving the phenolic hydroxyl groups
intact (Scheme 1) which were then utilized for post-polymerization
modiﬁcation by attachment of different substituents to tailor the
properties of resulting copolymers [86].
The amphiphilic polymers obtained by the attachment of
hydrophobic side chains exhibit comb like structures as shown in
Scheme 1. The process of micellization of the amphiphilic copoly-
mers (IP-PEG-O-C9-R) studied by 1H NMR longitudinal relaxationiphiles (IP-PEG-X-Cy-R).
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3057time (T1) [86] indicated that, in water, the hydrophobic segments
have a strong tendency to aggregate and generate the core of the
micelle that is covered by linkers and an external corona of PEG
loops as illustrated in Fig. 2.
Light scattering techniques were used to gather additional self-
assembly parameters i.e CMC (0.03e0.05) mM, the radius of gyra-
tion (Rg)w12e21 nm, hydrodynamic radius (Rh)w (6e13) nm, and
shape of micelles. The ratio of Rg/Rh suggests that the micelles have
a shape between a hollow sphere and a star-like sphere [87]. A
cartoon model of amphiphilic polymer developed by molecular
modeling study suggested aromatic units and alkyl chains to be in
close proximity and form an inner hydrophobic core. In this
process, the phenyl rings tend to stabilize the system by orienting
themselves in nearly parallel positions so as to maximize the pep
interactions. The alkyl chains tend to line up in a nearly parallel
fashion as shown in Fig. 3 [88].
Clearly the amphiphilic polymer system developed by Watter-
son et al. are not only effective for avoiding rapid renal exclusion,
but are also small enough to avoid undesirable uptake by the
reticulo endothelial system. Because of these miceller optimal
properties for drug delivery, they were evaluated for encapsulation
of two drugs molecules naproxen and aspirin [86]. The electronic
complementarity between host and guest established from 1H
NMR studies were reported to be the driving force for encapsula-
tion [88].
In vivo studies of (IP-PEG-C10-R) with encapsulated anti-
inﬂammatory agents (aspirin and naproxen) which applied topi-
cally on the skin of nude mice resulted in a signiﬁcant reduction in
inﬂammation [86]. The reduction in inﬂammation using nano-
spheres containing aspirin and naproxen was 62% and 64%,
respectively, but the empty nanospheres also exhibited some anti-
inﬂammatory activity (18%) as shown in Fig. 4.
The study also established that the nanosphere-mediated
delivery of aspirin and naproxen had signiﬁcantly better results
compared to the same aqueous dose (800 íg) prepared from
commercially available naproxen sodium (34%) and aspirin (32%)
(Fig. 4). The nanosphere-mediated delivery increased the efﬁcacy by
1.8e2.0 fold. The encapsulation of aspirin was also evaluated in
amphiphileswhere alkyl chainwas linkedwith ether (IP-PEG-O-C10),
ester (IP-PEG-OCO-C8), amide (IP-PEG-NHCO-C8), and maximum
loading was observed with amide linked systems (up to 26%) [89].
IP-PEG copolymers with phenolic hydroxyl at C-5 of iso-
phthalate, were found to be interesting for selective metal ion
interactions. The interaction of metal ions with organic ligands is ofFig. 2. Structure of PEGylated amphiphile anspecial interest to understand various biochemical processes
[90e95]. The interaction of IP-PEG block copolymers with various
metal cations (NaCl, KCl, CaCl2, AlCl3, BaCl2, MgCl2, and LiCl) was
studied by UV spectroscopy [96]. The interaction was selectively
observed with CaCl2. Furthermore, calcium bromide and calcium
iodide also interacted with the IP-PEG copolymers in an identical
manner indicating that the effect is a result of a cationic interaction
and is not signiﬁcantly inﬂuenced by the anion. The possibility of
interactions due to the effect of pH was excluded by performing
some control experiments. These results should be of relevance for
biological systems andmay ﬁnd applications in the ﬁeld of material
science and biology.
Watterson et al. also synthesized photo-responsive amphiphilic
polymers (IP-PEG-O-diazo) by attaching diazo alkyl chain (Scheme
1), which reduces the CMC tremendously, compared with amphi-
philes (IP-PEG-O-C9-R) carrying alkyl chains. An efﬁcient photo-
isomerization (trans e cis/cis e trans) was observed in organic
solvents chloroform and methanol, however this phenomenon was
not observed in aqueous solution. As a result, these amphiphiles
couldnot beexplored fordrugencapsulationandrelease studies [97].
Polymers made of naturally occurring building blocks are
preferred for biomedical applications because their degradation
products are non-toxic and can be easily metabolized by living
tissues. Encouraged by the development of novel chemo-enzymatic
approach, the efforts were made to synthesize various water
soluble PEGylated copolymers by using biologically important non-
toxic linker molecules such as coumarin, curcumin, glycerol, amino
acids, and sugar molecules (Fig. 5). Each of these block copolymers
have been explored for various biomedical applications. For
example, PEG-coumarin copolymers were evaluated for their anti-
inﬂammatory activity and have shown an enhanced and improved
ability to inhibit the TNF-a induced ICAM-1 (intercellular cell
adhesion molcecule 1) expression on human endothelial cells
compared to the coumarin linker itself [98]. PEG-curcumin block
copolymers enhanced the water solubility of curcumin due to
which the copolymers act as a potent Nrf2 activator which is
a central transcriptional factor for the regulation of the anti-oxidant
defense system and is considered a modiﬁer for several inﬂam-
matory diseases [99]. Amino acids, glycerol, and sugar containing
amphiphiles were evaluated for their self-assembly and drug
encapsulation studies.
PEG-amino acid [100,101] and PEG-glycerol copolymers after
post alkylation (Fig. 6) yield amphiphiles which self-assemble in
aqueous solution and form micelles.d its self-assembly in aqueous solution.
Fig. 3. Optimized geometry of amphiphiles in aqueous medium. Reproduced with permission from Ref. [88]. Copyright 2004 Royal Society of Chemistry.
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catalytic approachwherein a series of three amino acid diesters, i.e.,
diethylamino malonate, dimethyl aspartate, and diethyl glutamate
carrying a free amino group, were copolymerized with PEG [98].
The chemical method to obtain such copolymers is not only tedious
but also often involves organometallic catalysts and requires
additional processing to remove the trace amounts of organome-
tallic catalyst which are often difﬁcult to remove completely [102].
The free amino groups of the copolymers were used to attach alkyl
chains and the resulting amphiphiles (Fig. 7) were studied for their
self-assembly behavior in aqueous solution and found to be optimal
with amphiphile A2-PEG-C9. This has CMC of 2.2  104 mmol, Rg
18 nm, and aggregation number 15. These physical properties are
comparable to that of IP-PEG-O-Cy amphiphiles as shown in
Scheme 1.
Sharma et al. have synthesized lipase catalyzed chemo-selective
glycerol containing block copolymers by copolymerization of
glycerol with PEG-600 dimethyl ester. PEG diester was synthesized
by esteriﬁcation of the commercially available PEG-600 diacid. The
copolymers carried a free pendent secondary hydroxyl group
which was acylated with (C5/C7/C9) acid chlorides [103]. The
resultant amphiphiles (Fig. 8) self-assembled at a concentration of
103 M. Vitamin E encapsulation was evaluated in all the three
amphiphiles with C5/C7/C9 alkyl chain, andmaximum loading (22%)
was found for the amphiphile carrying C9 chain.
Haag et al. have synthesized carbohydrate containing amphi-
philes [104]. Suitable carbohydrate monomers carrying diol func-
tionality were obtained by the multistep synthesis starting from
diacetone-D-glucose and copolymerized with PEG-600 dimethyl
ester. Aggregation studies of the resulting copolymers PEG-S1/S2/
S3, (Fig. 9) revealed that they self-assembled in aqueous solution.
The polymeric aggregates were further explored for their drug
encapsulation properties in buffered aqueous solution of pH 7.4
(37 C) using nile red as a hydrophobic model compound by means
of UVeVis and ﬂuorescence spectroscopy. The drug loading
capacity of polymeric aggregates of copolymer (PEG-S2) bearingFig. 4. Anti-inﬂammatory properties of PEG nanospheres (NS) containing (a) aspirin and
Chemical Society.the hydrophobic ﬁve carbon alkyl chain was found to be signiﬁ-
cantly higher than that of the polymer bearing the benzylidene
moiety (PEG-S3). There was no signiﬁcant encapsulation in copol-
ymer (PEG-S1) which lacks hydrophobic content in comparison to
PEG-S2 and PEG-S3 copolymers. The nile red release study was
performed at pH 5.0 and 7.4 using ﬂuorescence spectroscopy. The
release of nile red from the copolymers (PEG-S3) and (PEG-S2) was
observed with a half-life of 3.4 and 2.0 h, respectively, at pH 5.0,
while no release was found at physiological pH 7.4 (37 C).
Watterson et al. modiﬁed IP-PEG copolymers as shown in
Scheme 1 for the transportation of vitamin E with high loading
capacity. For this purpose, polymeric nanocarriers containing the
covalently bound vitamin E have been designed and synthesized
using a chemo-enzymatic method (Scheme 2). The synthesized
nanocarriers can further be utilized to encapsulate vitamin E
through non-covalent interactions [105]. It was observed that the
covalent attachment of vitamin E to the polymer backbone
enhances the capacity of the polymer to encapsulate vitamin E, i.e.,
it increased from 17% (with fully functionalized alkyl chain) to 26%
(with 30% covalently attached vitamin E, and 70% alkyl chain
functionalization).
It was also found that the amphiphiles (fully functionalized with
alkyl chains) increased the efﬁcacy of the encapsulated vitamin E
against amyloid-b induced reactive oxygen species [106]. The
vitamin E containing nanocarriers are highly soluble in both water
and oil, making them suitable for both aqueous and non-aqueous
preparations. This approach allows a better control of the release
and bioavailability of vitamin E and can be used in combination
with other bioactive agents in various formulations for cosmetic
and pharmaceutical applications.
Advanced nanocarriers have also been produced by Watterson
et al. that may fulﬁll the parameters required for efﬁcient drug
delivery for an early detection of tumors by in vivo imaging
[107,108], and for a selective targeting of the therapeutics to the
cancer cells (Fig. 10). The design allows the customization of each
region of its micelle components, i.e. its surface, shell, and core for(b) naproxen. Reproduced with permission from Ref. [86]. Copyright 2004 Americal
Fig. 5. Lipase catalyzed condensation polymerization of linkers with PEG.
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targeting the cancer disease in advanced stages.
For MRI and speciﬁc tumor targeting purposes amphiphiles
were synthesized by copolymerization of two linkers, i.e. DM5O-
HIP (95%) and DM5NH2IP (5%), with equivalent moles of PEG diol
[108,109] as a hydrophilic component. In the resulting copolymer,
the amino groups were used for the covalent attachment of FITC
dye, and the phenolic hydroxyl groups were used for attachment
of peptide that carried a PEG spacer and, perﬂuoro alkyl chains.
The self-assembly of the resulting material contained perﬂuoro
alkyl chains in the core. The ﬂuoro alkyl moiety enabled their
usage as a potential nano-probe for 19F-MRI and the availability of
peptide on the outer surface of micelles could facilitate their
selective binding with tumor cell receptors and internalization in
the tumor cells by a receptor mediated endocytosis process
(Fig. 11).
These ﬂuoro amphiphiles (Fig. 10) have shown the capability to
encapsulate cargo 1H,1H,2H,2H-perﬂuorodecanol and enhance the
ﬂuorine signal in 19F-NMR up to 30% and 57% with ether linked and
amide linked perﬂuoro chains, respectively. The enhancement in
19F content makes these amphiphiles more suitable for MRI and
allows retention of the antitumor drug (Fig. 12) curcumin up to 14%.
Initial in vitro studies examining the cellular uptake of these
nanocarriers by radioactive labeling and analysis have shown thatFig. 6. Post modiﬁcatiothese particles target cancer cells more selectively than the normal
cells. This selectivity has been further demonstrated in the area of
drug delivery through increased cell death of targeted cancer cells
versus non-targeted cells when incubated with nanocarriers con-
taining the chemotherapeutic agent DOX.
Overall, based on the literature discussed herein, PEG containing
block copolymers point to the suitability of prepared polymeric
micelles as delivery vehicles compared to conventional drug
formulations for the efﬁcient administration of a range of thera-
peutic compounds. However, comb like architectures developed by
chemo-enzymatic method may ﬁnd application in the develop-
ment of newDDS for efﬁcient cell targeting and disease control. The
synthesized biodegradable polymers by this approach however
need further evaluation in vitro and in vivo.
The PEG containing block copolymeric micelles lack the avail-
ability of free functional groups on the outer surface of micelles due
to limited functional groups of PEG. This limits the post-modiﬁca-
tion of micelles. To overcome this problem and for the availability of
multivalent functional groups on the outer surface of the micelles,
the chemo-enzymatic approach could be useful for their
construction. Further there are some pros and cons of PEG dis-
cussed by Schubert et al. in a recent review article [41] which need
to be considered for new PEG containing micellar drug carrier
systems.n of copolymers.
Fig. 7. Amino acid containing amphiphiles.
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polyglycerols
Dendritic polymers, including perfect dendrimers and HBPs
with remarkable physical and chemical properties and unique
topological structures, are of immense importance for materials
science, catalysis, and biomedical research [110e115]. The unique
properties of dendrimers, such as their high degree of branching,
multivalency, globular architecture, well-deﬁned molecular
weight, large number of tunable surface groups, and an interior
that provides space as well as microenvironment for hosteguest
chemistry, makes them promising scaffolds for drug delivery. So
far, only two types of dendritic polymers, namely, polyamidoamine
(PAMAM) and poly(propylene imine) (PPI), have been
commercialized.
The synthesis and self-assembly of hyperbranched PGs
[116e118] are currently attracting considerable interest for appli-
cation in drug solubilization and delivery [43]. dPGs are structurally
deﬁned, consist of an aliphatic polyether backbone, and possess
multiple functional end groups [43,119,120]. Their size can be
precisely deﬁned between 5-20 nm [19,121]. PG-based architec-
tures demonstrate optimal biocompatibility on the cellular and
systemic levels. They have similar toxicological properties as PEG
which is classiﬁed as highly non-toxic for in vivo applications [43].
Thus, the development of new generation PG architectures with an
improved biocompatibility and designed drug release proﬁle will
further enhance our fundamental understanding of such systems
and could potentially lead to new DDS [122]. In recent years much
attention has been given to versatile architectures, most of which
are based on dendritic polyglycerol and classiﬁed according to the
chemical nature of the building units. The following section
reviews the recent progress in synthesis and application of non-
ionic dendritic polyglycerol based amphiphiles and dendritic core
multi-shell architectures.3.1. Linear-dendritic block copolymeric (LDBC) amphiphiles
Perfectly branched and highly symmetrical dendrimers have
a well-deﬁned number of end groups, and can be functionally
modiﬁed for controlling solubility, surface and interfacial proper-
ties, and encapsulation behavior [123e125]. Dendrimers have been
extensively studied for biomedical application in diagnostics andFig. 8. Glycerol containing amphiphiles.therapy [126,127]. They have been employed for the synthesis of
LDBC amphiphiles and used in DDS.
Frechet et al. described the ﬁrst synthesis of LDBCs in 1992 [128].
They reported the convergent synthesis of both AB diblock as well
as ABA triblock type structures with poly(benzyl ether) dendrons of
generation [G3] and [G4] and poly(ethylene oxide) (PEO) (Mn in the
range of 500e20,000 g/mol) as the linear polymer segment.
Nguyen and Hammond studied the properties of linear (PPO)-
dendritic (PAMAM) triblock copolymer (PAMAMePPOePAMAM) as
drug carriers [129]. The solution phase behavior of these block
copolymers was studied as a function of the generation of the
dendritic block, ionic strength, and solution pH. The triblock self-
assembles in aqueous media to form stable micelles with CMC
values ranging from 106e105 M and particle size ranging from 9
to 18 nm in diameter, with smaller diameters exhibited at higher
generations. These block copolymers encapsulated hydrophobic
drugs with high efﬁciency and showed sustained release of the
drug. Although it was shown that there was no pH dependence at
generation [G3] for drug release, but it was assumed that pH
dependence could be observed for higher generations.
Kanani et al. and Shukla et al. used linear-dendritic macromol-
ecules containing PEG and dendrimer block for transport of small
guest molecules such as 5,7-dibromo-8-hydoxy quinoline,
ibuprofen, congo red, and rose Bengal [130,131]. The linear-
dendritic copolymers/guest molecule complexes were stable at
room temperature for about 10 months and did not release the
encapsulated guest molecules. The controlled release of guest
molecules from linear-dendritic copolymers/guest molecule
complexes in vitro conditions was also investigated. It was found
that higher generations exhibited enhanced transport capacity, but
the drug release was also faster in comparison with lower den-
drimer generations. Furthermore, Shukla et al. also reported the
modiﬁcation of these LDBCs with benzyl alcohol and the pH-
dependent cleavage of the ester bonds over time [131]. Recently,
Zhou et al. studied the guest uptake into micelles formed of LDBCs
based on poly(butylenes oxide)-b-PEO as the linear part that is
connected to different generations of dend-PAMAM [132]. Light
scattering results indicated the formation of “ﬂower like” micelles
composed of a hydrophobic oxybutylene core and dendrimer
periphery in aqueous buffer solution. Drug solubilization in
micellar solutions of the conjugates was mainly done by the
incorporation of drug molecules in micelle cores, with a marginal
enhancement of solubility that was attributable to encapsulation in
the dendritic micelle coronas. The solubility of hydrophobic drugs
in 1 wt% micellar solutions increased up to 6-fold.
Haag et al. reported a modular approach for the synthesis of
well-deﬁned micellar constructs of non-ionic dendritic glycerol
based amphiphiles via click chemistry (Scheme 3) [133]. All the
amphiphiles featured a construction with dendronized hydrophilic
head groups [G1-G3] connected to hydrophobic segment of
aliphatic units via mono- or biaromatic spacers.
It was shown that the dendritic head group strongly inﬂuenced
the self-assembly as well as the aggregation number which led to
structurally persistent and highly deﬁned spherical micelles for
[G2] and [G3] dendrons. Due to the packing parameter, [G1]
amphiphiles preferably formed cylindrical micelles (Fig. 13) with
CMCs lying in the micro molar concentration range. The micelles
were tested as potential nanocarriers for hydrophobic compounds
and were shown to entrap the solvatochromic dyes nile red and
pyrene. Additionally, it was shown that the aromatic spacer group
in the hydrophobic part plays an important role for the binding and
transport of aromatic guest molecules. Besides the hydrophobic
effect, CH-p and pep interactions of arenes with other aromatic
units of the guest molecules seem to be particularly important for
solubilizing hydrophobic (aromatic) compounds [133].
Fig. 9. Carbohydrate containing amphiphiles and their aggregation in aqueous solution. Reproduced with permission from Ref. [104]. Copyright 2011 American Chemical Society.
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vehicles is the solubilization of hydrophobic drugs for which it is
necessary to investigate the effect of different core structures with
respect to solubilization, micelle (formulation) stability, and cyto-
toxicity. Haag’s group further extended the study of non-ionic
dendritic glycerol based amphiphiles composed of different
hydrophobic modiﬁcations: PG[G2]-DiAr-C18, PG[G2]-(C18)2, PG
[G2]-C18-BiP, and PG[G2]-C18-Naph and investigated them with
respect to solubilization and micelle stability using sagopilone, an
anti-cancer drug with low aqueous solubility (12 mg/L) [134]. The
cytotoxicity using HUVECs was also investigated and compared to
strandard excipients. With regard to the clinical application of
sagopilone as an anti-cancer therapeutic, a ﬁnal formulation
concentration of at least 1 g/L was required. The amphiphiles
formed spherical (7e10 nm), monodisperse (PDI 0.04e0.20)
micelles in buffered aqueous solution with the exception of the
double-chained amphiphile PG[G2]-(C18)2. All the micellesScheme 2. Synthesis of vitaminsolubilized sagopilone and showed a superior solubilization
behavior compared to standard excipients used in parenteral
formulations. The amphiphiles revealed a 2e3 fold higher solubi-
lization of sagopilone than Cremophor ELP and polysorbate 80
independent of the core structure. Sagopilone was best solubilized
in the presence of amphiphile with a diaromatic spacer (PG[G2]-
DiAr-C18) (Fig. 14) among all the dendritic amphiphiles tested.
Cytotoxicity studies with various functionalized amphiphiles
showed a clear structure-response relationship with the structure
comprising a naphthyl end group being the least cytotoxic. Its
actual cytotoxicity values were comparable to the standard excip-
ient Cremophor ELP and polysorbate 80 [134].
In addition to better solubility of the hydrophobic compounds,
a triggered release of guest molecules is highly desirable for
increasing pharmaceutical potential of the drugs and to reduce
their side effects. Attempts have been made to disrupt micellar
structures with different external stimuli like temperature [135],E containing amphiphiles.
Fig. 10. Amphiphile for MRI and targeting. Adapted from Refs. [107,108].
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the degradation of the amphiphilic molecule, which is irreversible
or can lead to other undesired effects. Another promising approach
is the light-induced isomerization of azobenzenes [138]. Haag et al.
recently developed a new non-ionic photo-switchable delivery
system and investigated it with regard to transport and release of
guest molecules [139]. The photo-responsive amphiphiles were
synthesized starting from 4-aminophenol under standard diazo-
tation conditions and then reacted with phenol. The hydrophobic
building block was attached to the azobenzene by etheriﬁcation
with the chosen aliphatic chain (C11 and C16). The attachment of
glycerol dendrons to the azo switch was carried out by ether-
iﬁcation using mesylated acetal-protected glycerol dendrons underFig. 11. Cartoon representation for micelles with ligands and theirbasic conditions. Subsequent removal of the acetal protecting
groups resulted in the azobenzene-containing amphiphiles.
All four PG-based amphiphiles (G2azoC11, G3azoC11, G2azoC16,
and G3azoC16) formed monodisperse (PDI 0.02e0.2), well-deﬁned
spherical (7e10 nm) micelles and offered a higher ability to
undergo transecis photoisomerization in comparison to a corre-
sponding linear mPEG amphiphile, which formed rather large ill-
deﬁned aggregates (205 nm, PDI 0.28). It was observed that the
size of the micelles inﬂuenced the photo-stationary state: the
smaller the micelles, the higher the photo-stationary state. These
ﬁndings were based on the larger empty space between the
molecules in smaller micelles formed from [G3] amphiphiles which
improved the photo response better than the densely packed largerspeciﬁc internalization in tumor cells. Adapted from Ref. [108].
F–
F–
F–
F–
F–
F–
–F
–F
–F
–F
–F
–F
Polymers with
perfluorocarbon side 
chains form micelles
In the same way as with 
hydrocarbon
Free perfluorocarbon
(cargo) can be 
encapsulated inside 
the micelle to 
increase 19F content
Anticancer drug
also encapsulated 
with perfluoro cargo
50-60 polymeric chains self assemble
into micelles in water above CMC
% of 19F can be increased 
with perfluorocargo for MRI
Fig. 12. Cartoon representation for nano micelles for drug delivery and imaging. Adapted from Ref. [107].
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3063aggregates of [G2] amphiphiles. Because the CMC was effectively
altered by light, these amphiphiles can be used for controlling the
solubilization and encapsulation of a guest molecule (Fig.15). It was
demonstrated that light attenuated uptake of nile red occurred
effectively by these photo-switchable amphiphiles. The effective-
ness of the switching inmodulating the aggregation behavior of the
amphiphiles is highly inﬂuenced by the photo-stationary state. A
high photo-stationary state led to a larger change in the CAC and
a larger overall effect on the solution behavior [139].
The use of PG dendrons allows a great diversity of architectures
by the convergent synthetic approach (Fig. 16).
Haag et al. reported the synthesis of a library of core-shell
architectures, based on a variety of aromatic cores attached to
different generations of PG dendrons (Fig. 16) [140,141]. The
synthetic protocol included the linking of the dendrons through
amidation [140] or click coupling [141]. Nile red was used as the
model drug for evaluating the encapsulation efﬁciency of these
architectures. No correlation between encapsulation and dendron
generation was found for PG dendrons coupled to a biphenyl core
via amide bonds. It was shown that the amount of encapsulated
nile red unexpectedly decreased with higher dendron generations.
However, because the complexes formed between nile red and the
dendritic PG derivatives were lower than 1:1 compositions in all
cases, larger aggregates were more likely to occur. On the other
hand, in the core-shell architectures obtained by the ‘click’
approach, UVeVis absorption spectra revealed a strong red shift of
the absorption band of nile red with a [G1] dendron complex which
suggests the presence of nile red in a very polar environment, e.g.
when it is surrounded by glycerol units. The hydrophobic cores
probably coupled with the smallest dendron [G1] to form aggre-
gates by pep interactions; therefore the dye was not accommo-
dated into the core. In higher generations, where the maximum
absorption shifted to lower wavelengths, nile red was usually
located in the hydrophobic core. The transport capacity of the dyeScheme 3. Synthesis of glycerol based non-ionicwas signiﬁcantly improved by expanding the core size which
indicates that an extended aromatic core is necessary for efﬁcient
encapsulation and transport of hydrophobic compounds. The
encapsulation of nile red was signiﬁcantly improved by a factor of
w200 by enlarging both core and dendrimer size.
3.2. Linear-hyperbranched block copolymeric (LHBC) amphiphiles
and dendronized polymers
HBPs have gained importance in recent years because they only
require a single polymerization step [142]. In contrast to perfectly
branched and monodisperse dendrimers, hyperbranched archi-
tectures exhibit large polydispersity in molecular weight and
structure due to the random branching process. They lead to
compact, globular shaped macromolecules because of spatial
restrictions of the branched topology and they are unlikely to form
entanglements, which is a well known feature for high molecular
weight linear copolymers [143]. These HBPs have been employed
for the synthesis of linear-hyperbranched amphiphiles by a few
research groups.
Frey et al. reported the preparation of a new type of linear-
hyperbranched surfactant consisting of a linear polymer chain
and a hPG segment [144]. These well deﬁned amphiphilic block
copolymers were prepared by anionic ring-opening multi-
branching polymerization of glycidol onto an end-functional
poly(propylene oxide) (PPO) macroinitiator (Scheme 4). Molec-
ular weights of the non-ionic amphiphiles obtained were all
monomodal, with moderate polydispersities of around 1.5. These
hPG homopolymers were investigated with respect to amphiphilic
properties. On comparison, these hPG homopolymers were closest
in chemical nature to Pluronics, although the structures do not
match completely, since Pluronics possess a symmetric triblock
structure with an interior PPO-segment. Based on an equal molar
mass range, the CMC values for the Pluronics are approximately tenamphiphiles via click chemistry approach.
Fig. 13. Schematic representation of micellization of various types of non-ionic dendritic glycerol based amphiphiles in water. Due to the packing parameter [G1] amphiphiles
preferably form cylindrical micelles. Reproduced with permission from Ref. [133]. Copyright 2010 American Chemical Society.
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poly(propylene oxide)-hb-poly(glycerol) was investigated via
a ﬂuorescence-probe method using diphenyl hexatriene as probe
molecule. For these linear-hyperbranched block copolymers the
CMC increases with the molecular weight of the hyperbranched
block. Since this system possesses amine functionality as the
linkage between the linear PPO and hPG block, the pH dependence
of the CMCwas also studied. The CMC constantly increased over the
whole range of the hydrophobic/hydrophilic ratio. Due to the
proven biocompatibility of PGs [146,147], the synthesized polymers
are of considerable interest for biomedical applications. It was
observed that the polymers render multi-drug resistant (MDR) to
cells sensitive to drug, decreasing the resistance factor [148]. The
linear-branched surfactants have been shown to inﬂuence the
transport of doxorubicin through biomembranes and into cells,
offering interesting possibilities for the chemotherapy of cancer
[148].
Dendronized polymers which combine the two concepts of
dendrimers and polymers, are a promising approach for generation
of smart materials. They can be prepared by four ways: direct
polymerization of dendron monomer (the macromonomer
approach), grafting dendrons to a linear polymer (attach-to
approach), divergent step-growth from a core of linear polymer
(divergent approach), and their combinations [149e151]. Amphi-
philic dendronized polymers have unique structural motifs [152]. In
nature they can be found in some ion channel membrane proteins,Fig. 14. Structural formula of the dendritic amphiphile used for the solubilization of sagop
bilization of the drug than Cremophor ELP and polysorbate 80 independent of the core stwhich means that amphiphilically dendronized polymers are of
interest as models for such proteins [126,153e155]. They may also
serve as novel and giant constituents of self-aggregated assemblies
and show interesting behavior at interfaces. A good candidate is
a dendronized polymer whose repeating units are equipped with
two sterically demanding substituents, one hydrophobic and the
other hydrophilic.
Mery et al. synthesized a series of dendronized polymers
carrying oligo-(ethyleneoxy) peripheral branches by post poly-
merization functionalization of multiallylic dendronized polymers
using a radical addition of mercaptans, namely, 2-
methoxy(ethoxy)ethanethiol and {2-(2 methoxyethoxy) ethoxy}
ethanethiol (Fig. 17) [156]. According to the hydrophilic and
hydrophobic balance, some polymers exhibited a thermores-
ponsive behavior in water solution, which is characterized by
a sharp LCST transition and a small hysteresis. The LCST was found
to increase with increasing DP. This uncommon behavior was
explained by two concomitant factors: a polymer dilution effect
and an increase of the apparent hydrophilicity of the polymers due
to a densiﬁcation of the EO coverage.
The structural properties of the polymers in solution have been
investigated by SAXS and SANS. By SAXS investigations and using
a spherocylinder shape model, the polymers in solution (below the
LCST) have been satisfactorily described. By increasing the DP, the
shape of the macromolecule was found to evolve from a spherical
to a spherocylinder shape with a constant cross section of ca. 40 Å.ilone in buffered aqueous solution. The amphiphile revealed a 2e3 fold higher solu-
ructure. Reproduced with permission from Ref. [134]. Copyright 2010 Elsevier.
Fig. 15. Proposed micelle disruption by light at a concentration between CMC (trans) and CMC (cis). UVeVis spectra of the light-attenuated solubilization of nile red. An uptake of
the dye can be seen in the sample which was kept in dark (gray), whereas the switched sample showed no adsorption of the dye (black). Reproduced with permission from
Ref. [139]. Copyright 2011 Royal Society of Chemistry.
Fig. 16. Structural variety of core-shell architectures based on PG dendrons.
Scheme 4. Synthesis of amphiphilic LHBP based on linear hy
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family of dendronized polymers by functionalizing ethylene
oxideeepichlorohydrin copolymer with aromatic ether dendrons
based on 3,5-dibenzyl ether (Fig. 18) [157]. The polymers were
characterized by FTIR spectroscopy and tested for possible appli-
cation as an electrolyte for lithium-ion batteries. The polymer with
increased dendritic residue exhibited improved ionic conductivity
and excellent thermal stability. Thermogravimetric analysis and
differential scanning calorimetry were performed to determine the
thermal stability and crystallinity of the polymeric material.
Incorporation of bulky dendritic pendent moieties into the polymer
backbone effectively broke down the crystallinity of these
polymers.
Dendronized polymers are currently under intense investiga-
tion with respect to various applications, including the synthesis of
hierarchically structured materials, catalysis, applications in the
biosciences, such as ion channel mimics and DNA compactization,
as well as optoelectronic applications [149].3.3. Hyperbranched core-shell architectures
Physical aggregates of amphiphilic molecules, such as micellar
structures, are frequently proposed as drug-delivery systems
because of their non-covalent assembly [37]. However, these
aggregates can be unstable under shear force and other kinds of
environmental effects as a result of their weak assembly. They are
also not very suitable for the active release of the encapsulated
species through the application of an external trigger, such as pHdrophobic PPO and hyperbranched hydrophilic PG [144].
Fig. 17. Two-step preparation procedure of EO-functionalized dendronized polymers
PG1bis-EOx and PG1tris-EOx by (i) anionic polymerization of allyl-ended dendritic
macromonomers followed by (ii) thiol-ene coupling with short EO chains. Reproduced
with permission from Ref. [156]. Copyright 2011 American Chemical Society.
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molecules into these dendritic architectures have been studied by
several research groups [158e169] relatively little is known about
the active release of the encapsulated guest molecules by pH-
triggered cleavage of the shell in the physiological pH range
(Fig. 19). An alternate approach is the covalent modiﬁcation of
dendritic macromolecules with an appropriate shell that results in
stable micelle-type structures, which are suitable for the non-Fig. 18. Structures of dendronized polymers.covalent encapsulation of guest molecules (Fig.19) [170]. The size of
these dendritic nanocarriers can be exactly deﬁned in the range of
5e20 nm. The encapsulation of guest molecules by these dendritic
nanocarriers is driven by non-covalent interactions (ionic, H-
bonding, and van der Waals interactions) and can be tailored for
various drugs at the same time and thus have an advantage over
polymer-drug conjugates, which have to be synthesized individu-
ally in an extensive multi-step synthesis.
Dendritic polymers with their regular and well-deﬁned unim-
olecular architecture can be chemically modiﬁed either at the core
(to increase hydrophobicity) or at the shell (to increase hydrophi-
licity) thereby tailoring the solubility proﬁle of such nanotransport
systems. Among the various polymeric drug carriers known today
[115,121,171], dendritic polymers based on PG and with deﬁned
core-shell type architectures have shown good transport capacities
for several poorly water-soluble bioactive molecules. Several
investigations covered the inﬂuence of post-modiﬁcation of the PG
scaffold in an attempt to increase transport capacity and/or efﬁ-
ciency, decrease inherent toxicity, tune structural topology, and
impart targeting modalities. Micelles as well as inverted micellar
structures have been constructed and their carrier properties
investigated for several bioactive molecules.
PEGylation of hPG is a promising method for rendering aqueous
solubility, minimizing immunogenicity, and increasing the blood
circulation half-life of the resulting nanocarriers, as well as
mimicking the structure of so-called “stealth” liposomes [172].
Brooks et al recently reported an efﬁcient synthesis of hydro-
phobically modiﬁed as well as PEG-grafted hyperbranched PGs
using 1,2-epoxyoctadecane and a-epoxy, u-methoxy PEG 350
(MPEG-epoxide) as the monomer, respectively [173,174]. Initially
hyperbranched PG of molecular weight 7 kDa was prepared by
anionic ROMBP of glycidol. An equivalent of 2e5% of the OH groups
were derivatized with C18 alkyl chains and 20e40% of the OH
groups were modiﬁed with mPEG 350 chains by sequential addi-
tion of the corresponding epoxides. The obtained structures carried
alkyl chains at the core and PEG moieties grafted on the shell
(Fig. 20).
The unimolecular micellar nature of the molecules with
different alkyl chains/PEG composition was probed by multiangle
laser light scattering (MALLS). Due to low intrinsic viscosity, these
scaffolds were extremely promising candidate for human serum
albumin (HSA) substitutes [173]. The encapsulation efﬁciency was
evaluated using paclitaxel and pyrene as model compounds. Fluo-
rescence studies revealed that the hydrophobic molecules are most
likely to be located in the hydrophobic pockets of the unimolecular
structures [175]. The solubility of paclitaxel in water was increased
from 0.3e1 mg/mL up to 2 mg/mL after encapsulation in the
nanocarriers, without any considerable effect on the size of
the unimolecular micelles. The release proﬁle was characterized
by a burst release phase followed by a slower sustained-release
phase [175].
These structures presented mucoadhesive properties. Pacli-
taxel was incorporated into these mucoadhesive nanoparticles
and was evaluated as an intravesical agent against non-muscle-
invasive bladder cancer [176]. Though the encapsulated pacli-
taxel was slightly less potent than the free drug in vitro, the
in vivo studies showed that the mucoadhesive formulation of
paclitaxel was signiﬁcantly more effective in reducing orthotopic
bladder tumor growth than the standard Cremophor-EL formu-
lation of paclitaxel (Fig. 21). Relative tumor growth with pacli-
taxel complex was reduced to 15% of the control compared to 66%
for the free paclitaxel group. The complex was well tolerated in
mice and the resulting stabilized level of hematuria and body
weight with zero mortality indicated no sign of systemic toxicity.
These amphiphilic systems were reported to adsorb onto the
Fig. 19. Unimolecular dendritic nanocarriers for encapsulation of biologically active compounds. Controlled release after triggered shell cleavage (e.g. pH-controlled). Reproduced
with permission from Ref. [170]. Copyright 2002 Wiley.
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sustained drug release characteristics in vitro using the drug
paclitaxel [175].
Furthermore, Frey et al. [178] have described the synthesis of
a,un-linear-hyperbranched PEG-PG heterotelechelics with a single
amino moiety in the a-position and subsequent attachment of
biotin in this position. They have used this material subsequently
for non-covalent bioconjugation, which can be achieved with or
without a linear PEG-spacer. Paleos et al. [179] prepared functional
HBPs based on a commercially available polyether polyol that bear
PEG chains with folate targeting ligands on their end. They found
that PEG chains, in addition to their well-established function as
protective coating for drugs and their carriers, enhanced the
encapsulation efﬁciency and controlled the release of ﬂuorescent
probes, pyrene, and anti-cancer drug tamoxifen. DLS revealed
unimicellar encapsulation of the guest molecules within the PG-
PEG structure. A salt-triggered release was observed upon addi-
tion of sodium chloride and was enhanced as the concentration of
salt in themedium increases. The cationization of the poly(ethylene
glycol) moieties of the carriers by the sodium ions leads to the
formation of complexes. This may lead to the replacement of
solubilized drug by the metal ions and, therefore, release of the
drug can occur.
Frey et al. described the use of hPGs for the preparation of
amphiphilic molecular nanocapsules for hydrophilic guests [164].Fig. 20. Synthetic scheme for the hydrophobically derivatized PG. ReprConstruction of molecular nanocapsules was demonstrated using
narrow poly-dispersity PGs and simple esteriﬁcation of only
a certain fraction of hydroxyl groups (43e93%) with hydrophobic
fatty acid chains (Scheme 5), thereby leaving residual hydroxyl
moieties and hence, the inner sphere of the molecule remained
highly hydrophilic (Fig. 22).
The considerable ﬂexibility of the polyether structure permits
the hydroxyl groups to arrange in a manner that represents
a solvating environment for polar guest molecules in apolar
solvents. These hyperbranched molecular nanocapsules were thus
able to solubilize a distinct average number of polar molecules in
their interior, depending on the core size and substituents. This
encapsulation which is based only on a hydrophobically shielded,
hydrophilic solvating microenvironment represents a different
principle in comparison to the topological entrapment observed for
some dendrimer-based structures. From light scattering measure-
ments it was tentatively concluded that the solvating species are
present in an unimolecular form in organic solvents, thus, repre-
senting “inverted unimolecular micelles”. Release of the encapsu-
lated dyes was achieved by cleaving the ester bond, thus, removing
the hydrophobic molecular shield of the nanocapsules.
The polyfunctional polyol architecture of dPG polymers makes
them suitable for multiple functionalization. They hold consider-
able promise as binding agents for drug delivery due to their three-
dimensional shapes and availability of a large number of functionaloduced with permission from Ref. [173]. Copyright 2008 Elsevier.
Fig. 21. In vivo evaluation of hydrophobic PG-paclitaxel complex against orthotopic
bladder tumor. Reproduced with permission from Ref. [176]. Copyright 2008 Wiley.
S. Gupta et al. / Polymer 53 (2012) 3053e30783068groups for suitable modiﬁcations [180e183]. The presence of
primary and secondary alcoholic groups provides a platform for the
selective modiﬁcation and tuning of the physio-chemical proper-
ties so that these architectures can be further used as potential drug
carriers. Haag and Sharma et al. reported for the ﬁrst time chemo-
enzymatic regioselective modiﬁcation of the dPG with PEG chains
via the primary hydroxyl groups and further alkylation of the
remaining hydroxyl groups to generate well-deﬁned architectures
with an easily hydrolyzable ester linkage [184]. The dPG was ﬁrst
PEGylated in a regioselective manner using the PEG carboxylic acid
(Mnw 1 kDa) and Novozyme-435 as a biocatalyst. The esteriﬁcation
reaction primarily occurred through the primary hydroxyl groups
of PG leaving the secondary hydroxyl groups intact. PEGylated PG
was then acylated through its remaining hydroxyl groups by acid
chlorides of varying chain lengths to yield amphiphilic polymeric
architectures (Scheme 6).
The solubilization behavior of these polymeric architectureswas
studied by means of UVeVis spectroscopy using nile red as
hydrophobic model compound (Fig. 23). It was observed that the
amount of dye solubilized by the polymer increased with the
polymer concentration which suggests that these systems exist as
aggregates at low concentrations (<0.1 g/L). The degree of solubi-
lization was also inﬂuenced by the increase in size of the alkyl
chain. The polymer with undecenoyl chain showed better transport
behavior than other polymers, which may be due to the more
hydrophobic contribution of the alkyl chain and the possibility ofScheme 5. Synthesis of amphiphilicpep interactions between the terminal oleﬁnic bond and aromatic
ring system of nile red that resulted in more compact aggregates
and thus led to a decrease in particle size with improved poly
dispersity index values. These systems were found capable of
releasing the encapsulated nile red at pH 5.0 (e.g. endosomal pH),
while no release was observed at pH 7.4 (physiological pH).
Furthermore, cell viability studies of these polymers showed that
they are relatively non-toxic. These successful efforts in tuning the
synthesis and physio-chemical properties of dPG based amphi-
philic polymeric architectures as novel DDSs are currently being
explored as biodegradable dendritic nanocarriers for biomedical
applications [184].
The architecture of hyperbranched dPG consists of two types of
hydroxyl functionalities, arising from linear glycerol units in prox-
imity to the core and from the terminal glycerol units in the
periphery of the macromolecule (Fig. 24b) and has no distin-
guishable interior or periphery like the perfect dendrimers. An
effective and highly reproducible “chemical differentiation”
strategy to generate core-shell architectures has been reported by
the Haag group, where these two types of hydroxyl groups can be
chemically differentiated to generate core-shell type architecture
within the hyperbranched PG scaffold [185]. The 1,2-diols of the
terminal glycerol units were selectively converted to the corre-
sponding acetals or ketals in order to distinguish between the
interior (close to the focal unit) and periphery (distant from the
focal unit) of the macromolecule, which was possible because the
remaining linear glycerol units remained unaffected by this trans-
formation. A subsequent reaction of the linear units with alkyl
halides, such as allyl or benzyl chloride, under phase transfer
condition yielded the corresponding polyether polyketals. Selective
deprotection of 1,2-ketals was achieved with an acidic ion-
exchange resin to give “core” functionalized PGs.
This “chemical differentiation” strategy allowed a selective
tailoring of the PG scaffold to contain a hydrophobic interior or
a hydrophobic periphery, thereby modulating the distribution
coefﬁcients of the generated structure between organic and
aqueous phases. Such selective ketal functionalized hyperbranched
PGs were found to be effective for the encapsulation and transport
of polar guests (e.g. dyes or drugs) and the creation of special
micro-environments as demonstrated by the shaded area in Fig. 24
[186]. The extensive branch-on-branch topology of these polymers
leads to typical properties associated with core-shell architectures,
i.e., nanosegregation depending on the polarity of the “core” and
the “shell”.
Haag’s group has also investigated the effect of a speciﬁc core
modiﬁcation of the hydroxyl groups of linear glycerol units with
hydrophobic biphenyl moieties on encapsulation and transport
capacities (Fig. 25) [187]. Amphiphilic nanocarriers containing
unsubstituted and donor-/acceptor-substituted biphenyl groups in
the core were synthesized in an effective three- to four-step
procedure by employing etheriﬁcation and Suzuki-coupling reac-
tions. The generated amphiphiles were then employed to solubilizemolecular nanocapsules [164].
Fig. 22. Synthesis of an inverted unimolecular micelle from a hyperbranched polyol by partial hydrophobization of the end groups and subsequent take-up of a water-soluble guest
molecule (small blue circles: free hydroxyl groups, small red rings: hydroxyl groups esteriﬁed with alkyl chains). Reproduced with permission from Ref. [164]. Copyright 1999Wiley.
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3069pyrene and the commercial drug nimodipine, a calcium antagonist
used for the treatment of heart diseases and neurological disorders.
A major advantage of these amphiphilic PGs is that a hydro-
phobic core could be designed to tailor certain polymeredrug
interactions. Consequently, it was possible to design dendritic
architectures with a speciﬁc interaction proﬁle for functional drug
molecules. As example, the core-shell PG derivative with 30,40-
dimethoxybiphenyl-4-methyl ether groups in the core showed
speciﬁc pep interactions as detected by UV spectroscopy in the
case of nimodipine complexation, in addition to non-speciﬁc
hydrophobic hosteguest interactions (Fig. 25). These observations
indicated the formation of aggregates. The modiﬁed dendritic
polymers were found to self-assemble around the drug molecules
in a controlled manner, as revealed by DLS and AFM analysis
(Fig. 26) [188]. CAC measurements revealed that these ﬂexible,
amphiphilic macromolecules self-assemble to extremely deﬁned
supramolecular structures with diameters of around 10 nm in theScheme 6. Synthesis of amphiphilic PG-PEG architectures. Reprodupresence of the drug at very low concentrations (CAC typically ca.
106 M).
In addition to the transport of different drug molecules, these
structures exhibited a substantial release of nimodipine in SEC
column ﬁltration where highly dilute conditions could be
mimicked.
Haag’s group further modiﬁed the core of the dPGs with
biphenyl groups and perﬂuorinated chains [188]. Due to the
increased hydrophobicity of the core the newly developed
systems were used to selectively solubilize hydrophobic
(aromatic) dyes and drug molecules such as pyrene, nile red, and
nimodipine. The encapsulation of the guest molecules was driven
by weak non-covalent interactions such as hydrophobic, van der
Waals interactions, and pep stacking. The transport capacity
increased 450-fold for nile red, 47-fold for nimodipine, and 37-
fold for pyrene at a polymer concentration of only 0.1 wt.%. The
aggregation properties were studied by surface tensionced with permission from Ref. [184]. Copyright 2011 Wichtig.
Fig. 23. Model for drug solubilization and release. Reproduced with permission from Ref. [184]. Copyright 2011 Wichtig.
S. Gupta et al. / Polymer 53 (2012) 3053e30783070measurements and scanning force microscopy (SFM). The diam-
eter of the formed supramolecular aggregates was 20 nm and CAC
was observed to be 2  106 M. Encapsulation experiments in
water revealed that cores functionalized with 45% of biphenyl
groups showed better transport capacity than those with a lower
degree of functionalization (27%). However, the polymer became
insoluble in water if the degree of functionalization exceeded 50%.
Polymers with a perﬂuorinated core were substantially hydro-
phobic in nature and showed better transport capacity [188]. This
phenomenon has particularly been observed with nile red
encapsulation.
The selective and reversible shell functionalization of dPG
scaffolds (Fig. 24c) allows preparation of core-shell structures with
reverse micellar character. The self-association of amphiphilic
polymers in non-aqueous solvents should thus yield nano-
structures with a polar core surrounded by a hydrophobic shell.
This type of inverted micellar systems has been extensively inves-
tigated in encapsulation of oligonucleotides, metal complexes, and
several water-soluble dyes and drugs [189]. The potential use of
such systems in pharmaceutical applications is highly promising
since they can be used in oleaginous formulations thereby
providing better stability against enzymatic degradation and
facilitating absorption through biological barriers such as the
intestinal membrane. In addition, these systems could allow theX = Core
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Wiley.controlled delivery of active compounds by subcutaneous admin-
istration. The hydrophobic character of the shell also makes these
architectures attractive candidates for use in hydrophobic devices
like teﬂon-based bone replacement materials and transdermal
patches [43].
Haag et al. developed a way to synthesize such amphiphilic
dendritic architectures for potential application in pH-dependent
delivery of the encapsulated guest by using acid-sensitive link-
ages (acetals/ketals) for the PG shell [170]. The synthetic route
involved a selective condensation reaction of the 1,2-diol units by
a one-pot pathway, based on two consecutive transketalization
reactions (Fig. 24c). The selective core-shell architectures obtained
were highly amphiphilic with a hydrophobic shell and hydrophilic
interior due to the remaining, unreacted hydroxyl groups. Such
‘molecular nanocarriers’ do not exhibit aggregation in dilute solu-
tion, as demonstrated by DLS, and thus represent inverse unim-
olecular micelles.
The transport capacity of these systems was governed by core-
molecular weight, alkyl-chain length, and degree of functionaliza-
tion. A minimum core size of 3 kDa and a highly branched archi-
tecture are required for successful encapsulation of the guest
molecules [170], while the degree of alkylation should be around
50% and the alkyl chains should have a minimum length of 10
carbons for efﬁcient transport of guest molecules.O
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Fig. 25. PG core-shell architecture after post-modiﬁcation of the core-hydroxyl groups with biphenylmethyl ether groups and its speciﬁc interaction with the drug nimodipine as
exempliﬁed by a batochromic shift in the UV-Vis spectrum. Reproduced with permission from Ref. [187]. Copyright 2007 Wiley.
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3071The transport capacities of these molecular nanocarriers were
evaluated using congo red as an easily detectable polar model
compound and it was observed that the transport capacity of these
nanocarriers critically depends on the packing density of the shell.
It was found that acetal functionalization of PG core with C16
aldehyde containing one alkyl chain per diol unit resulted in an
effective degree of alkyl functionalization of 25% and a poor
transport capacity (0.15 congo red molecules). The ketal function-
alized nanocarrier with two alkyl chains per diol unit and 45%
effective alkyl functionalization, however, can transport up to 13
congo red molecules indicating an optimal core-shell functionali-
zation, as a higher degree of ketal functionalization (55%), could
transport only two dye molecules and the encapsulation process
was very slow. The transport properties of these nanocarriers were
then studied with different guest molecules containing polar or
ionic organic groups as model systems. Many organic dyes, such as
bromophenol blue, congo red, methyl orange, methyl red, and
ﬂuorescein, all of which contain polar anionic sulfonate or
carboxylate groups and sodium counterions, were readily encap-
sulated and transported by these nanocarriers. A controlled release
of encapsulated congo red from such a system was achieved in
chloroform by lowering the pH of the aqueous phase, which
promoted the cleavage of the hydrophobic shell and the further
release of the dye to the aqueous phase (Fig. 27) [170].
Haag et al. developed core-shell architecture [190] by PG
PEGylation, which resulted in efﬁcient encapsulation, although the
release proﬁles need to be improved to overcome the strong
hosteguest interaction. The dendritic nanocarriers were prepared
by attaching tri-PEGylated benzaldehydes of varying lengths to the
hyperbranched PG amine by using pH-labile imine bonds (Fig. 28).Fig. 26. Aggregation of core modiﬁed PG as revealed by AFM (left) and supramolecular
aggregate of dye loaded coreeshell architectures (right). Reproduced with permission
from Ref. [188]. Copyright 2010 Wiley.The designed structures were able to encapsulate the anti-
cancer agent DOX and a near-infrared imaging dye, indo-
tricarbocyanine for optical imaging. It was found that nanocarriers
with the shortest PEG chain (n ¼ 4) and a denser shell showed the
best encapsulation efﬁciency (up to 5 molecules of DOX or NIR dye/
PEGylated PG). The pH-dependent release of the DOX-nanocarrier
was investigated by incubation at pH 4.0 or 7.4 (37 C) and by
dialyzing the sample over time and determining the amount of
released DOX in the ultraﬁltrate using HPLC. It was observed that
a certain fraction of DOX (w20%) can be released in a pH-
dependent manner, but the major amount of the drug remained
associated with the nanocarrier (plateau level reached after 4 h)
under the chosen experimental conditions. In an early study with
nudemice, the DOX nanocarrier could be dosed up to 24mg/kg free
DOX equivalents intravenously which was a signiﬁcant increase in
the MTD compared to free DOX MTD [191]. Cytotoxicity experi-
ments with the nanocarriers revealed higher IC50 values for three
cancer cell lines (3.3e31 mM) than for free DOX (0.02e0.39 mM),
suggesting that the DOX loaded nanocarriers exhibited much
lower antiproliferative activity than the free drug which may be
due to an insufﬁcient release of DOX from the complex.
The ability of the nanocarriers to localize in tumors in vivo was
demonstrated by ﬂuorescence imaging of tumor-bearing mice
(Fig. 29) with the indotricarbocyanineenanocarrier complex [190].
The near-infrared ﬂuorescence imaging allowed an easy visualiza-
tion of the tumor-accumulation of the dye-PG complexes since the
near-infrared and far-red light (650e900 nm) can avoid strong
absorption by red blood cells and water thus allowing the light to
pass through the body of the mouse to the depth of several centi-
meters. Increased levels of tissue ﬂuorescence suggested that the
nanocarrier altered the biodistribution of the free dye which led to
higher concentrations in the nanocarrier format.
Haag et al. recently developed water-soluble core-shell unim-
olecular transporters by tandem coordination-ring opening
hyperbranched polymerization [45]. A late transition metal-
catalyzed chain walking polymerization (CWP) was employed to
generate a highly nonpolar dendritic polyethylene (PE) core, fol-
lowed by anionic ring-opening polymerization of glycidol to graft
a hydrophilic hyperbranched polyglycerol shell (Fig. 30). This
amphiphilic core-shell architecture was then investigated for its
capability as molecular nanotransporters for hydrophobic
compounds pyrene and nile red. Evidence from ﬂuorescence
spectroscopy, light scattering, and electron microscopy, supported
the unimolecular transport mechanism by the core-shell
copolymer.
Fig. 27. Encapsulation of polar guest molecules into organic phase. Cleavage of the shell leads to the release of the encapsulated guest back to the aqueous phase. Reproduced with
permission from Ref. [170]. Copyright 2002 Wiley.
S. Gupta et al. / Polymer 53 (2012) 3053e30783072The applicability of the PE-PG core-shell copolymer was further
demonstrated by the unimolecular transport of hydrophobic dye
nile red into living cells under extremely high and biologically
relevant dilute conditions. The results clearly indicated the
successful uptake of nile red into the A549 lung tumor cells incu-
bated with dilute solution of the PE-PG copolymer, which was in
sharp contrast to a small molecule amphiphile (Fig. 30), which
showed only a weak nile red ﬂuorescence. The results suggest
potential applicability of such core-shell molecular transporters in
the administration of poorly water-soluble drugs [45].
Fine tuning the hyperbranched polymeric architecture in
a predictable fashion is of signiﬁcant interest for various applica-
tions [110,111]. Zimmerman et al. reported the covalent linking of
the allyl and homoallyl ether end groups of dendrimers using ring-
closing metathesis (RCM) reaction [192,193]. In addition to creating
molecularly imprinted dendrimers [194e196] and organic nano-
tubes [197], cross-linking of the end groups was shown to produce
a signiﬁcant decrease in the size of the dendrimer [198]. These
organic nanoparticles also became more rigid. The extent of cross-
linking could be controlled, thus allowing the dendrimer size and
rigidity to be ﬁnely and independently modulated. Haag group
designed and investigated a series of smart systems with PG scaf-
folds that have a cross-linked outer shell and cleavable or tunableFig. 28. Structure of an idealized fragment of the pH-labile core-shell architecture (left). The
pH-values (right). Reproduced with permission from Ref. [190]. Copyright 2009 Elsevier.moieties at the core-shell. The RCM of the allyl groups located on
the PG surface generated the cross-linked dendritic architectures
with a covalently closed dense shell system (Fig. 31) [199,200]. The
complete hydrogenation of the alkene groups on the shell led to
fully water soluble polymers. They displayed a crown ether-type
binding of picrate ions in organic phases, with ion afﬁnity and
selectivity comparable to several crown ethers. Investigations to
assess the capacity of these architectures to effectively host organic
dyes like rose bengal, thymol blue, and congo red demonstrated
that a larger loop size in the shell exhibited better complexation
properties while smaller cavities within the PG scaffold assured
a higher stability of the hosteguest complexes [201].
To investigate the hosteguest stability, the polymer-dye solu-
tions were extracted for a few minutes with water. After phase
separation, the UV absorption of the organic phase was measured
again (Fig. 32) and a clear difference between allylated and RCM
cross-linked HPGs was observed. Whereas the hydrophilic rose
bengal and thymol blue sodium salt were extracted to the water
layer from its organic soluble complex with allylated hPG, the dye
complex with RCM cross-linked hPG was sufﬁciently stable and the
dye remained in the chloroform layer. Indeed, the cross-linked host
2 did not liberate the dye even after 12 h of shaking with water and
the use of sonication.amount of cleaved imine bonds as determined by IR signals for nanocarriers at different
Fig. 29. Fluorescence image of a tumor-bearing mouse (F9 teratocarcinoma) 6 h after
injection of nanocarrier-NIR dye complex. Reproduced with permission from Ref. [190].
Copyright 2009 Elsevier.
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3073To further achieve a controlled release of the guest molecules,
Haag’s group developed photo-responsive cross-linked systems by
the introduction of o-nitrobenzyl groups within the shell (Fig. 33)
[201]. The photolytic degradation of the polymer was then studied
with UVeVis spectroscopy. The photodegradable nanocapsules
retained the capacity and selectivity for encapsulating bioactive
molecules, while modiﬁcation of the building blocks allowed
substantial control over hosteguest stability.
The photo initiated guest release of rose bengal was studied
from these nanocarriers. The light-triggered release of the dye from
the dye complex in chloroformwas conﬁrmed by irradiation of the
solution at 350 nm monochromatic light. Fig. 34 shows the
controlled release of the dye as a function of UV irradiation time.
It was demonstrated that these systems show high capacity and
selectivity in guest encapsulation. The modiﬁcation of the buildingFig. 30. PE-PG core-shell copolymer (left) and structure of amphiphile (right). Reprodblocks, in particular the outer shell, allows control of the
hosteguest complex stability. The presence of the hexa(ethylene
glycol) outer-shell instead of the hexene shell increased the
stability of the formed hosteguest complexes but led to difﬁculties
in guest release. However, the introduction of the hexene shell
assured a high release of guest molecules from the nanocapsules
(up to 80%).3.4. Hyperbranched core multi-shell architectures
The fundamental problem of most carrier systems is their
limited matrix compatibility. They generally transport nonpolar
molecules into an aqueous environment [158,202] or polar mole-
cules into a hydrophobic environment such as an organic medium,
in the case of an inverted micellar architecture [159,160,170].
Therefore, the generation of nanocompartments that are compat-
ible with various environments should solve many solubility and
stability problems of active agents. Haag et al. developed a novel
kind of CMS architecture for a more universal transport behavior
that was inspired by the molecular mimicry of a liposome based on
a hyperbranched PG core surrounded by double-layered shells
[203,204]. The synthesis of such dendritic multi-shell architectures
was performed by coupling alkyl chain to monomethylated PEGs
which were in turn coupled to hyperbranched PG amine as shown
in Fig. 35. The multi-shell nanocarriers self-assemble into supra-
molecular aggregates above awell-deﬁned threshold concentration
(CAC). Single nanocarriers with a size range of 8e9 nm coexisted
with their larger aggregates with diameters of 20e50 nm. These
multi-shell nanocarrier aggregates not only accommodated polar
and nonpolar guest molecules but also adapted to various envi-
ronmental polarity conditions ranging from toluene to water. In
contrast to already existing micelle-analog systems, this new
architecturemimics the structure of a liposome on an unimolecular
basis.
The therapeutic potential of the synthesized CMS architectures
was evaluated for their skin penetration properties and compared
to those of solid lipid nanoparticles (SLN) and oil-in-water (o/w)
cream. Nile red was used as a probe molecule and it was found that
CMS systems signiﬁcantly enhanced the skin penetration of the dye
[205].
The encapsulation of nile red in the CMS architectures was time
and concentration dependant. With increasing nile red concen-
tration, the surface was assumed to be totally clad with the dye
molecules. From this concentration on, corresponding to a diffusion
time of 10e20 min, nile red diffused into the agglomerate of the
particles sitting ﬁrst at the inter-particular spaces and, with still
increasing diffusion time, within the matrix of individual particles.uced with permission from Ref. [45]. Copyright 2012 American Chemical Society.
Fig. 31. Schematic representation of allylated (1), RCM cross-linked (2), dihydroxylated (3), and RCM cross-linked and dihydroxylated hPG (4). Adapated from Ref. [200].
Fig. 32. Photographs of encapsulated rose bengal sodium salt in polymers 1 and 2
before (left) and after 5 min extraction with water (right). Reproduced with permission
from Ref. [200]. Copyright 2009 American Chemical Society.
Fig. 34. Release of rose bengal from photo-responsive cross-linked systems by UV
irradiation (l ¼ 350 nm). Reproduced with permission from Ref. [201]. Copyright 2009
Wiley.
S. Gupta et al. / Polymer 53 (2012) 3053e30783074It was observed that the concentration of nile red, physically
encapsulated into a stable dendritic CMS system, increased 8-fold
in the stratum corneum and 13-fold in the epidermis as opposed
to when loaded in o/w cream. Despite the degradation at the
stratum corneum surface, SLN enhanced skin penetration less
efﬁciently (3.8 and 6.3-fold) than CMS nanoparticles. Viable human
keratinocytes showed an internalization of both nanocarriers
within 30 min of incubation.
These CMS systems were further studied for the topical treat-
ment of skin diseases as they facilitate the skin penetration of the
loaded hydrophilic agents, which was demonstrated using the dye
rhodamine B as a model compound [203,205]. The cutaneous
uptake of rhodamin B loaded onto SLN, CMS nanotransporters, and
a conventional cream was studied, respectively. Representative
ﬂuorescence staining (Fig. 36) indicated an enhanced dye pene-
tration of the CMS architectures loaded into the viable epidermis
and dermis after application of the nanoparticulate carrier systems
compared to the cream. The penetration of rhodamin B into the
viable epidermis increased up to 11.5-fold following the application
of CMS nanotransporters, which shows the potential of such
structures as topical DDSs.
A new CMS architecture was developed in the Haag group in an
attempt to obtain core double-shell architectures with differentFig. 33. Formation of light-responsive nanotransporters with o-nitrobenzyl groups in th
permission from Ref. [201]. Copyright 2009 Wiley.densities and ﬂexibility (Fig. 37) [206]. These new architectures
were synthesized from simple and non-toxic building blocks by
applying straight forward and heavy metal-free synthesis. The
periphery of the hPG was modiﬁed with different lengths of
aliphatic chains which were further decorated with monoamino
HPGs (HPG-NH2). The synthesized multi-shell polymers possessed
low polydispersities which is an important issue for many potential
applications, especially for biomedical purposes. Another impor-
tant characteristic of the synthesized CMS architectures was the
hydrodynamic radius (Rh), which was found to be w1.5 nm for
3 kDa hPG core. The Rh of the synthesized architectures increased
up to 5.2 nm for a 10-carbon aliphatic inner shell with 1100 Da hPG
outer shell. These observations indicate that a 10-fold increase in
the molecular weight leads to a dramatic increase in the molecules
size. The effect of the individual building blocks on guest encap-
sulation was studied by varying the hydrophobic and hydrophilic
domain of the polymers.
The universal nanotransport character of the obtained CMS was
conﬁrmed by encapsulation of polar guest molecules as rose bengale outer shell obtained by intramolecular ring-closing metathesis. Reproduced with
Fig. 35. (a) Synthesis of CMS architecture and2 (b) schematic representation of a typical liposome structure (top) and the dendritic multi-shell architecture (bottom). Reproduced
with permission from Ref. [204]. Copyright 2007 Wiley.
Fig. 36. Rhodamin B penetration into pig skin: (a) staining of pig skin following the application of 0.004% rhodamin B loaded cream, (b) SLN, and (c) CMS architecture for 6 h.
Reproduced with permission from Ref. [205]. Copyright 2009 Elsevier.
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3075and congo red, and water insoluble compounds, as nimodipine, nile
red, and pyrene. Moreover, this new type of CMS system, in contrast
to the previously reported one, acts as unimolecular nanocarrier
system for nonpolar guest molecules, with transport capacities ofFig. 37. Schematic representation of double-shell architecture with hyperbranched
core and highly branched outer shell linked by an alkyl chain of varying lengths.
Reproduced with permission from Ref. [206]. Copyright 2009 American Chemical
Society.1.5 guest molecules per nanocarrier. However, for polar guest
molecules, the formation of uniform aggregates with a diameter of
70 nm and with transport capacities of up to 10 guests per nano-
carrier was detected. This may be due to the fact that the dye
molecules are preferentially located on the outer shell of the
polymer and therefore may be acting as non-covalent linkers
between molecules.
4. Conclusions
Polyether based amphiphilic nanocarriers have evolved rapidly
over the last decade circumventing the limitations of conventional
surfactants such as toxicity, undesirable side effects, and hyper-
sensitivity reactions; and thus have led to an ease in delivery of
active components. The gold standard-PEG is currently the most
used polyether polymer for therapeutic applications with a safety
proﬁle, non-toxicity, high biocompatibility, and decreased interac-
tion with the blood components. The low CMCs of these nano-
carriers enable the delivery of active components even at high
dilution in the blood stream. Although these PEG-based amphi-
philic nanocarriers demonstrate optimal biocompatibility over
cellular and systemic levels, they have possible drawbacks such as
degradation under stress, accumulation in the body above an
uncertain excretion limit and interaction with the immune system
generating various immune responses. Furthermore, limited end
group functionality of PEG leads to intrinsically low modiﬁcation
potential at the polyether backbone.
As potential alternative to PEG, polyglycerol (PG) based
perfect dendrons and well-deﬁned hyperbranched amphiphilic
S. Gupta et al. / Polymer 53 (2012) 3053e30783076architectures are potential polyether scaffolds, which are under
current investigations. The biocompatibility and toxicity proﬁle of
PG runs parallel to PEG, and has been classiﬁed as highly biocom-
patible and non-toxic for in vivo applications. The topological 3D
dendritic architecture and tunable polyol end groups of PG allow
multiple modiﬁcations and make it a versatile candidate for
supramolecular self-assembly and biomedical applications when
compared to linear PEG based amphiphiles. However, the biode-
gradability of the PG core is still an unresolved issue when used at
high molecular weights (>100 kDa).
Although it is still at an early stage of research, polyglycerol
based amphiphilic architectures have shown great potential as
a versatile material for supramolecular self-assembly and delivery
of active components. Strong efforts are still needed to overcome
the limitations of these existing amphiphilic nanocarriers and to
investigate the translation of these nanocarriers into the clinics.
Also, new chemo-enzymatic approaches to biodegradable poly-
ether architectures need to be addressed in the future. Further
advances in the ﬁeld may open new arenas to enhance the versa-
tility of polyether based amphiphilic scaffolds and will present
a novel platform for the next generation of drug delivery systems.
Acknowledgments
We acknowledge ﬁnancial support from Bundesministerium fur
Bildung und Forschung (BMBF), Indo-German Science & Tech-
nology Centre (IGSTC), Departments of Science & Technology (DST),
Delhi, Deutscher Akademischer Austausch Dienst (DAAD), SFB 765,
and University of Delhi. Furthermore, Dr. Pamela Winchester is
thanked for carefully proofreading this manuscript and Achim
Wiedekind is thanked for help in designing the cover picture.
References
[1] The therapeutic index of a drug is deﬁned as the ratio of the toxic dose to the
therapeutic dose.
[2] The term “polymer therapeutics” was coined by Helmut Ringsdorf and Ruth
Duncan. Other research groups use the more general term “nanomedicine”.
[3] Gros L, Ringsdorf H, Schupp H. Angew Chem Int Ed Engl 1981;20(4):305e25.
[4] Duncan R. Nat Rev Drug Discov 2003;2(5):347e60.
[5] Duncan R. Targeting and intracellular delivery of drugs. In: Meyers RA,
editor. Encyclopedia of molecular cell biology and molecular medicine.
Weinheim, Germany: Wiley-VCH Verlag, GmbH & Co. KGaA; 2005.
p. 163e204.
[6] Yalkowsky SH, Roseman TJ. Techniques of solubilization of drugs. New York:
Marcel Dekker Inc; 1981. pp. 91e134.
[7] Ray R, Kibbe AH, Rowe R, Shleskey P, Weller P. Handbook of pharmaceutical
excipients. Washington, DC: APhA Publications; 2003.
[8] Shuai X, Merdan T, Schaper AK, Xi F, Kissel T. Bioconjug Chem 2004;15:
441e8.
[9] Xie J, Wang CH. Pharm Res 2005;22(12):2079e90.
[10] Suh H, Jeong B, Rathi R, Kim SW. J Biomed Mater Res 1998;42(2):331e8.
[11] Kim SY, Lee YM. Biomaterials 2001;22:1697e704.
[12] Lavasanifar A, Samuel J, Kwon GS. Adv Drug Deliver Rev 2002;54:169e90.
[13] Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V. Biochim Bio-
phys Acta 1984;797:363e8.
[14] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. J Control Release 2000;65:
271e84.
[15] Matsumura Y, Maeda H. Cancer Res 1986;46:6387e92.
[16] Maeda H. Adv Drug Deliver Rev 2001;46:169e85.
[17] Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A. J Drug Target 2007;15(9):
553e84.
[18] Torchilin VP. Nat Rev Drug Discov 2005;4:145e60.
[19] Haag R. Angew Chem Int Ed 2004;43:278e82.
[20] Srinivas R, Samanta S, Chaudhuri A. Chem Soc Rev 2009;38(12):3326e38.
[21] Karmali PP, Chaudhuri A. Med Res Rev 2007;27(5):696e722.
[22] Liu F, Qi H, Huang L, Liu D. Gene Ther 1997;4(6):517e23.
[23] Yang JP, Huang L. Gene Ther 1997;4(9):950e60.
[24] Zelphati O, Uyechi LS, Barron LG, Szoka Jr FC. Biochim Biophys Acta 1998;
1390:119e33.
[25] Shimizu T, Masuda M, Minamikawa H. Chem Rev 2005;105:1401e43.
[26] Hill JP, Jin W, Kosaka A, Fukushima T, Ichihara H, Shimomura T, et al. Aida T
Sci 2004;304:1481e3.
[27] Vemula PK, John G. Acc Chem Res 2008;41(6):769e82.[28] Claussen RC, Rabatic BM, Stupp SI. J Am Chem Soc 2003;125:12680e1.
[29] Sierra L, Lopez B, Gil H, Guth JL. Adv Mater 1999;11(4):307e11.
[30] Ruiz-Hitzky E, Letaief S, Prevot V. Adv Mater 2002;14(6):439e43.
[31] Zhang Q, Ariga K, Okabe A, Aida T. J Am Chem Soc 2004;126:988e9.
[32] Kabanov AV, Kabanov VA. Adv Drug Deliver Rev 1998;30:49e60.
[33] Allen C, Maysinger D, Eisenberg A. Colloids Surf B 1999;16:3e27.
[34] Kwon GS, Kataoka K. Adv Drug Deliver Rev 1995;16:295e309.
[35] Rosler A, Vandermeulen GWM, Klok HA. Adv Drug Deliver Rev 2001;53:
95e108.
[36] Miyata K, Christie RJ, Kataoka K. React Funct Polym 2011;71:227e34.
[37] Kataoka K, Harada A, Nagasaki Y. Adv Drug Deliver Rev 2001;47:113e31.
[38] Nishiyama N, Kataoka K. Pharmacol Ther 2006;112:630e48.
[39] Osada K, Christie RJ, Kataoka K. J R Soc Interface 2009;6:S325e39.
[40] Lee Y, Kataoka K. Soft Matter 2009;5:3810e7.
[41] Knop K, Hoogenboom R, Fischer D, Schubert US. Angew Chem Int Ed 2010;
49:6288e308.
[42] Obermeier B, Wurm F, Mangold C, Frey H. Angew Chem Int Ed 2011;50:
7988e97.
[43] Calderon M, Quadir MA, Sharma SK, Haag R. Adv Mater 2010;22:190e218.
[44] Khandare J, Calderon M, Dagia NM, Haag R. Chem Soc Rev 2012;41:2824e48.
[45] Popeney CS, Lukowiak MC, Boettcher C, Schade B, Welker P, Mangoldt D,
et al. ACS Macro Lett; 2012. doi:10.1021/mz300083y.
[46] Lin WJ, Juang LW, Wang CL, Chen YC, Lin CC, Chang KL. J Exp Clin Med 2010;
2(1):4e10.
[47] Torchilin VP. Pharm Res 2006;24(1):1e16.
[48] Woodle MC, Lasic DD. Biochim Biophys Acta 1992;1113:171e99.
[49] Molineux G. Cancer Treat Rev 2002;28:13e6.
[50] Lee JH, Lee HB, Andrade JD. Prog Polym Sci 1995;20:1043e79.
[51] Croy SR, Kwon GS. Curr Pharm Des 2006;12(36):4669e84.
[52] Kwon GS, Forrest ML. Drug Dev Res 2006;67:15e22.
[53] Torchilin VP. J Control Release 2001;73:137e72.
[54] Nathan A, Zalipsky S, Ertel SI, Agathos SN, Yarmush ML, Kohn J. Bioconjug
Chem 1993;4:54e62.
[55] Howard MD, Ponta A, Eckman A, Jay M, Bae Y. Pharm Res 2011;28:2435e46.
[56] Alani AWG, Bae Y, Rao DA, Kwon GS. Biomaterials 2010;31:1765e72.
[57] Xiong XB, Lavasanifar A. Nano 2011;5(6):5202e13.
[58] Yokoyama M, Fukushima S, Uehara R, Okamoto K, Kataoka K, Sakurai Y, et al.
J Control Release 1998;50:79e92.
[59] Kabanov AV, Batrakova EV, Alakhov VY. J Control Release 2002;82:189e212.
[60] Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Pharm Res
1995;12:192e5.
[61] Liggins RT, Burt HM. Adv Drug Deliver Rev 2002;54:191e202.
[62] Hagan SA, Coombes AGA, Garnett MC, Dunn SE, Davies MC, Illum L, et al.
Langmuir 1996;12:2153e61.
[63] Allen C, Han J, Yu Y, Maysinger D, Eisenberg A. J Control Release 2000;63:
275e86.
[64] Letchford K, Zastre J, Liggins R, Burt H. Colloids Surf B 2004;35:81e91.
[65] Matsumura Y, Kataoka K. Cancer Sci 2009;100:572e9.
[66] Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al.
Brit J Cancer 2005;92:1240e6.
[67] Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Breast Cancer Res
Treat 2008;108:241e50.
[68] Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto SI, Hamaguchi T, et al.
Cancer Res 2006;66:10048e56.
[69] Matsumura Y. Adv Drug Deliver Rev 2011;63:184e92.
[70] Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Br J
Cancer 2005;93:678e87.
[71] Kabanov AV, Alakhov V, Yu V. Crit Rev Ther Drug 2002;19:1e73.
[72] Kabanov AV, Betrakova EV, Miller DW. Adv Drug Deliver Rev 2003;55:
151e64.
[73] Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. Nanoscale Res Lett
2009;4:1530e9.
[74] Gao Q, Liang Q, Yu F, Xu J, Zhao Q, Sun B. Colloids Surf B 2011;88:741e8.
[75] Kulthe SS, Inamdar NN, Choudhari YM, Shirolikar SM, Borde LC, Mourya VK.
Colloids Surf B 2011;88:691e6.
[76] Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Int J Nanomedicine
2010;5:1057e65.
[77] He Y, Zhang Y, Gu C, Dai W, Lang M. J Mater Sci Mater Med 2010;21:567e74.
[78] He Y, Zhang Y, Xiao Y, Lang M. Colloids Surf B 2010;80:145e54.
[79] Yan J, Ye Z, Chen M, Liu Z, Xiao Y, Zhang Y, et al. Biomacromolecules 2011;12:
2562e72.
[80] Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. J Control Release 2008;126:
122e9.
[81] Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K. Biomacromolecules
2007;8:202e8.
[82] KimS, Shi Y, Kim JY, Park K, Cheng JX. Expert OpinDrugDeliv 2010;7(1):49e62.
[83] Mahmud A, Xiong XB, Lavasanifar A. Eur Pharm Biopharm 2008;69:923e34.
[84] Xiong XB, Falamarzian A, Garg S, Lavasanifar A. J Control Release 2011;155:
248e61.
[85] Danprasert K, Kumar R, Cheng MH, Gupta P, Shakil NA, Prasad AK, et al. Eur
Polym J 2010;39(10):1983e90.
[86] Kumar R, Chen MH, Parmar VS, Samuelson LA, Kumar J, Nicolosi R, et al. J Am
Chem Soc 2004;126:10640e4.
[87] Checot F, Lecommandoux S, Gnanou Y, Klok HA. Angew Chem Int Ed 2002;
41:1339e43.
S. Gupta et al. / Polymer 53 (2012) 3053e3078 3077[88] Sharma SK, Kumar R, Kumar S, Mosurkal R, Parmar VS, Samuelson LA,
Watterson AC, Kumar J. Chem Commun; 2004:2689e91.
[89] Pandey MK, Tyagi R, Gupta B, Parmar VS, Kumar J, Watterson AC. J Macromol
Sci A 2008;45:932e8.
[90] Fish RH, Jaouen G. Organometallics 2003;22:2166e77.
[91] Ma JC, Dougherty DA. Chem Rev 1997;97:1303e24.
[92] Gokel GW, Barbour LJ, Ferdani R, Hu J. Acc Chem Res 2002;35:878e86.
[93] Dougherty DA. Science 1996;271:163e8.
[94] Dougherty DA, Stauffer DA. Science 1990;250:1558e60.
[95] Kumpf RA, Dougherty DA. Science 1993;261:1708e10.
[96] Sharma SK, Kumar S, Tyagi R, Barry EF, Kumar J, Watterson AC, et al.
Microchem J 2008;90:89e92.
[97] Tyagi R, Pandey MK, Malhotra S, Kumar R, Kumar J, Parmar VS, et al.
J Macromol Sci A 2007;44:1283e7.
[98] Pandey MK, Balwani S, Sharma PK, Parmar VS, Ghosh B, Watterson AC. Eur J
Pharm Sci 2010;39:134e40.
[99] Pandey MK, Kumar S, Thimmulappa RK, Parmar VS, Biswal S, Watterson AC.
Eur J Pharm Sci 2011;43:16e24.
[100] Tyagi R, Kumar R, Pandey MK, Kumar J, Parmar VS, Watterson AC.
J Macromol Sci A 2008;45:958e63.
[101] Kumar R, Tyagi R, Parmar VS, Samuelson LA, Watterson AC, Kumar J.
J Macromol Sci A 2003;A40:1283e93.
[102] Ellwood P. Chem Eng 1967;74:98e100.
[103] Gupta S, Pandey MK, Levon K, Haag R, Watterson AC, Parmar VS, et al.
Macromol Chem Phys 2010;211:239e44.
[104] Bhatia S, Mohr A, Mathur D, Parmar VS, Haag R, Prasad AK. Bio-
macromolecules 2011;12:3487e98.
[105] Kumar R, Tyagi R, Watterson AC, Parmar VS, Kumar J. Cosmetic Nanotech-
nology: polymers and Colloids in Cosmetics. ACS Symp Ser 2007;961:
139e48.
[106] Shea TB, Ortiz D, Nicolosi RJ, Kumar R, Watterson AC. J Alz Dis 2005;7:
297e301.
[107] Pandey MK, Tyagi R, Ke Yang, Fisher RJ, Colton CK, Kumar J, et al. Polymer
2011;52(21):4727e35.
[108] Pandey MK, Tyagi R, Kumar R, Parmar VS, Watterson AC, Kumar J, et al.
Polym Preprints 2007;96:855e6.
[109] Kumar R, Tyagi R, Parmar VS, Samuelson LA, Kumar J, Watterson AC. Mol
Divers 2003;6:287e95.
[110] Frechet JMJ, Tomalia DA. Dendrimers and other dendritic polymers. New
York: John Wiley & Sons, Ltd; 2001.
[111] Newkome GR, Mooreﬁeld CN, Vögtle F. Dendrimers and dendrons: concepts,
synthesis, applications. 1st ed. Weinheim: Wiley-VCH; 2001.
[112] Heerbeek RV, Kamer PCJ, van Leeuwen PWNM, Reek JNH. Chem Rev 2002;
102:3717e56.
[113] Astruc D, Chardac F. Chem Rev 2001;101:2991e3023.
[114] Newkome GR, He E, Mooreﬁeld CN. Chem Rev 1999;99:1689e746.
[115] Lee CC, MacKay JA, Frechet JMJ, Szoka FC. Nat Biotechnol 2005;23(12):
1517e26.
[116] Sunder A, Hanselmann R, Frey H, Mulhaupt R. Macromolecules 1999;32:
4240e6.
[117] Haag R, Sunder A, Stumbé J. J Am Chem Soc 2000;122:2954e5.
[118] Sunder A, Mulhaupt R, Haag R, Frey H. Adv Mater 2000;12:235e9.
[119] Khandare J, Mohr A, Calderon M, Welker P, Licha K, Haag R. Biomaterials
2010;31(15):4268e77.
[120] Turk H, Haag R, Alban S. Bioconjug Chem 2004;15:162e7.
[121] Haag R, Kratz F. Angew Chem Int Ed 2006;45:1198e215.
[122] Mohr A, Haag R. Applications of supramolecular chemistry: spramolecular
drug delivery systems. Taylor & Francis publishers, Schneider J; in press.
[123] Fréchet JMJ. J Polym Sci Part A Polym Chem 2003;41:3713e25.
[124] Fischer M, Vögtle F. Angew Chem Int Ed 1999;38:884e905.
[125] Aulenta F, Hayes W, Rannard S. Eur Polym J 2003;39:1741e71.
[126] Zeng F, Zimmerman SC. Chem Rev 1997;97:1681e712.
[127] Majoros IJ, Williams CR, Baker Jr JR. Curr Top Med Chem 2008;8(14):
1165e79.
[128] Gitsov I, Wooley KL, Fréchet JMJ. Angew Chem Int Ed Engl 1992;31:1200e2.
[129] Nguyen PM, Hammond PT. Langmuir 2006;22:7825e32.
[130] Adeli M, Zarnegar Z, Dadkhah A, Hossieni R, Salimi F, Kanani A. J Appl Polym
Sci 2007;104:267e72.
[131] Namazi H, Adeli M, Zarnegar Z, Jafari S, Dadkhah A, Shukla A. Colloid Polym
Sci 2007;285:1527e33.
[132] Zhou Z, D’Emanuele A, Lennon K, Attwood D. Macromolecules 2009;42:
7936e44.
[133] Trappmann B, Ludwig K, Radowski MR, Shukla A, Mohr A, Rehage H, et al.
J Am Chem Soc 2010;132:11119e24.
[134] Richter A, Wiedekind A, Krause M, Kissel T, Haag R, Olbrich C. Eur J Pharm Sci
2010;40:48e55.
[135] Nakayama M, Okano T, Miyazaki T, Kohori F, Sakai K, Yokoyama M. J Control
Release 2006;115:46e56.
[136] Xue YN, Huang ZZ, Zhang JT, Liu M, Zhang M, Huang SW, et al. Polymer 2009;
50:3706e13.
[137] Saji T, Hoshino K, Ishii Y, Goto M. J Am Chem Soc 1991;113:450e6.
[138] Teitel A. Naturwissenschaften 1957;44:370e1.
[139] Kordel C, Popeney CS, Haag R. Chem Commun 2011;47:6584e6.
[140] Wyszogrodzka M, Möws K, Kamlage S, Wodzinska J, Plietker B, Haag R. Eur J
Org Chem; 2008:53e63.[141] Wyszogrodzka M, Haag R. Chem Eur J 2008;14:9202e14.
[142] Jikei M, Kakimoto M. Prog Polym Sci 2001;26:1233e85.
[143] Wurm F, Frey H. Prog Polym Sci 2011;36:1e52.
[144] Istratov V, Kautz H, Kim YK, Schubert R, Frey H. Tetrahedron 2003;59:
4017e24.
[145] Lopes JR, Loh W. Langmuir 1998;14:750e6.
[146] Kainthan RK, Muliawan EB, Hatzikiriakos SG, Brooks DE. Macromolecules
2006;39:7708e17.
[147] Kainthan RK, Janzen J, Levin E, Devine DV, Brooks DE. Biomacromolecules
2006;7:703e9.
[148] Demina T, Grozdova I, Krylova O, Zhirnov A, Istratov V, Frey H, et al.
Biochemistry 2005;44:4042e54.
[149] Frauenrath H. Prog Polym Sci 2005;30:325e84.
[150] Zhang A, Shu L, Bo Z, Schluter AD. Macromol Chem Phys 2003;204(2):
328e39.
[151] Chen Y, Xiong X. Chem Commun 2010;46:5049e60.
[152] Schlüter AD, Rabe JP. Angew Chem Int Ed 2000;39:864e83.
[153] Voyer N, Lamothe J. Tetrahedron 1995;51:9241e84.
[154] Voyer N, Robitaille M. J Am Chem Soc 1995;117:6599e600.
[155] Schenning APHJ, Elissen-Roman C, Weener JW, Baars MWPL, Gaast SJV,
Meijer EW. J Am Chem Soc 1998;120:8199e208.
[156] Roeser J, Moingeon F, Heinrich B, Masson P, Arnaud-Neu F, Rawiso M, et al.
Macromolecules 2011;44(22):8925e35.
[157] Chakrabarti A, Juilfs A, Filler R, Mandal BK. Solid State Ionics 2010;181:
982e6.
[158] Newkome GR, Mooreﬁeld CN, Baker GR, Saunders MJ, Grossman SH.
Angew Chem 1991;103:1207e9. Angew Chem Int Ed Engl 1991;30:
1178e1180.
[159] Jansen JFGA, de Brabander-van den Berg EMM, Meijer EW. Science 1994;
266:1226e9.
[160] Stevelmans S, van Hest JCM, Jansen JFGA, van Boxtel DAFJ, de Brabander-van
den Berg EMM, Meijer EW. J Am Chem Soc 1996;118:7398e9.
[161] Schenning APHJ, Ellissen-Roman C, Weener JW, Baars MWPL, van der
Gaast SJ, Meijer EW. J Am Chem Soc 1998;120:8199e208.
[162] Chechik V, Zhao M, Crooks RM. J Am Chem Soc 1999;121:4910e1.
[163] Sunder A, Kramer M, Hanselmann R, Mulhaupt R, Frey H. Angew Chem 1999;
111:3758e61.
[164] Sunder A, Kramer M, Hanselmann R, Mulhaupt R, Frey H. Angew Chem Int Ed
1999;38:3552e5.
[165] Kojima C, Kono K, Maruyama K, Takagishi T. Bioconjug Chem 2000;11:
910e7.
[166] Liu M, Kono K, Frechet JMJ. J Control Release 2000;65:121e31.
[167] Kleij AW, van de Coevering R, Gebbink RJMK, Noordman AM, Spek AL, van
Koten G. Chem Eur J 2001;7:181e92.
[168] Stiriba SE, Kautz H, Frey H. J Am Chem Soc 2002;124:9698e9.
[169] Kojima C, Haba Y, Fukui T, Kono K, Takagishi T. Macromolecules 2003;36:
2183e6.
[170] Krämer M, Stumbé JF, Türk H, Krause S, Komp A, Delineau L, et al. Angew
Chem Int Ed 2002;41:4252e6.
[171] Satchi-Fainaro R, Duncan R, Barnes CM. Adv Polym Sci 2006;193:1e65.
[172] Allen TM, Cullis PR. Science 2004;303:1818e22.
[173] Kainthan RK, Janzen J, Kizhakkedathu JN, Devine DV, Brooks DE. Biomaterials
2008;29:1693e704.
[174] Kizhakkedathu JN, Brooks DE, Kainthan RK. USPTO ptent aplication
20080292579.
[175] Kainthan RK, Mugabe C, Burt HM, Brooks DE. Biomacromolecules 2008;9:
886e95.
[176] Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, et al. BJU
Int 2008;103:978e86.
[177] Liu Z, Janzen J, Brooks DE. Biomaterials 2010;31:3364e73.
[178] Wurm F, Klos J, Rader HJ, Frey H. J Am Chem Soc 2009;131:7954e5.
[179] Tziveleka LA, Kontoyianni C, Sideratou Z, Tsiourvas D, Paleos CM. Macromol
Biosci 2006;6:161e9.
[180] Duncan R, Izzo L. Adv Drug Deliver Rev 2005;57:2215e37.
[181] Svenson S, Tomalia DA. Adv Drug Deliver Rev 2005;57:2106e29.
[182] Dufès C, Uchegbu IF, Schatzlein AG. Adv Drug Deliver Rev 2005;57:
2177e202.
[183] Gillies ER, Frechet JMJ. Drug Discov Today 2005;10:35e43.
[184] Kumar S, Mohr A, Kumar A, Sharma SK, Haag R. Int J Artif Organs 2011;34(2):
84e92.
[185] Haag R, Stumbé JF, Sunder A, Frey H, Hebel A. Macromolecules 2000;33:
8158e66.
[186] Haag R, Krämer M, Stumbé JF, Kautz H. Polym Mat Sci Eng 2001;84:69.
[187] Türk H, Shukla A, Rodriguez PCA, Rehage H, Haag R. Chem Eur J 2007;13:
4187e96.
[188] Kurniasih IN, Liang H, Rabe JP, Haag R. Macromol Rapid Commun 2010;31:
1516e20.
[189] Newkome GR, Mooreﬁeld CN, Vögtle F. Dendritic molecules: concepts,
Syntheses, perspectives. Weinheim: VCH; 1996.
[190] Xu S, Luo Y, Graeser R, Warnecke A, Kratz F, Hauff P, et al. Bioorg Med Chem
Lett 2009;19:1030e4.
[191] Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V, et al.
Toxicol Appl Pharmacol 1985;79:412e22.
[192] Wendland MS, Zimmerman SC. J Am Chem Soc 1999;121:1389e90.
[193] Elmer SL, Zimmerman SC. J Org Chem 2004;69:7363e6.
S. Gupta et al. / Polymer 53 (2012) 3053e30783078[194] Zimmerman SC, Wendland MS, Rakow NA, Zharov I, Suslick KS. Nature 2002;
418:399e403.
[195] Mertz E, Zimmerman SC. J Am Chem Soc 2003;125:3424e5.
[196] Beil JB, Zimmerman SC. Chem Commun; 2004:488e9.
[197] Kim Y, Mayer MF, Zimmerman SC. Angew Chem 2003;115:1153e8.
[198] Lemcoff NG, Spurlin TA, Gewirth AA, Zimmerman SC, Beil JB, Elmer SL, et al.
J Am Chem Soc 2004;126:11420e1.
[199] Zimmerman SC, Quinn JR, Burakowska E, Haag R. Angew Chem 2007;119:
8312e5.
[200] Burakowska E, Quinn JR, Zimmerman SC, Haag R. J Am Chem Soc 2009;131:
10574e80.
[201] Burakowska E, Zimmerman SC, Haag R. Small 2009;5:2199e204.
[202] Savic R, Luo L, Eisenberg A, Maysinger D. Science 2003;300:615e8.
[203] Küchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, et al. Eur J
Pharm Biopharm 2009;71:243e50.
[204] Radowski MR, Shukla A, von Berlepsch H, Böttcher C, Pickaert G, Rehage H,
et al. Angew Chem Int Ed 2007;46:1265e9.
[205] Kuchler S, Abdel-Mottaleb M, Lamprecht A, Radowski MR, Haag R, Schafer-
Korting M. Int J Pharm 2009;377:169e72.
[206] Burakowska E, Haag R. Macromolecules 2009;42(15):5545e50.Shilpi Gupta received her Ph.D. in organic
chemistry in 2011 from the University of
Delhi, India under the supervision of
Professor Sunil K. Sharma. She is currently
a Postdoctoral Fellow in the Research Group
of Professor Dr. Rainer Haag at the Freie Uni-
versität Berlin. Her research interest is in the
development of amphiphilic nanocarriers
based on PEG and dendritic polyglycerols for
intelligent delivery of drugs, genes and
imaging probes.Rahul Tyagi received his Ph.D. in organic
chemistry in 2008 from the University of
Massachusetts, Lowell (USA) under the
supervision of Professor Arthur C. Watterson.
He moved to the University of Southern
Denmark, Odense for his Postdoctoral studies
in medicinal chemistry with Dr. Trond Ulven.
He is currently working as a senior Post-
doctoral Fellow with Professor Dr. Rainer
Haag at Freie Universität Berlin. His research
is focused on the design and synthesis of
bioactive molecules, biocatalytic reactions,
and delivery of drugs and bioactive
compounds involving multifunctional poly-
meric biomaterials.Virinder S. Parmar was born in 1948 in Alla-
habad (India). He did his B. Sc. Honours (1968),
M.Sc. (1970) and PhD (1978) from the Univer-
sity of Delhi and has Postdoctoral/Visiting
Scientist research experience of nearly ten
years. He joined the University of Delhi as
lecturer in chemistry at St. Stephen’s College in
1970 and was appointed as Reader in the
Department of Chemistry in 1984 and was
appointed as Professor of Chemistry in 1996. He
has served the University of Delhi as Chairman
of the Board of Research Studies in Science
during November 2007 to August 2008 and as
Head of theDepartmentof Chemistry fromMay
2007 to April 2010.He has publishedmore than
400 research papers in international journals in
addition to being co-inventor on 15 US and
Indian patents. His research interest includes
Nanotechnology, Synthetic Organic Chemistry,
Bio-catalysis, Nucleic Acid Chemistry, Medic-
inal Chemistry, Green Chemistry, Advanced
Materials and Chemistry of Natural Products.Sunil K. Sharma (born in 1963) joined the
Department of Chemistry in March 2004 as
Associate Professor and became Professor in
2010. He obtained BSc (Hons), MSc, and PhD
degrees from the University of Delhi. His
doctoral work was in the areas of synthetic
and natural product chemistry. He has Post-
doctoral/Visiting Scientist research experi-
ence of more than ten years in USA and
Europe. He is recipient of International
Authors Award from Royal Society of Chem-
istry (UK) in 1999, and several other awards.
He has published more than 75 research
papers in international journals of repute.
Sharma’s research interests include: Organic
synthesis, Bio-catalysis, Chemistry of natural
products, and Nanotechnology.Rainer Haag obtained his PhD with A. de
Meijere at the University of Göttingen in 1995.
After postdoctoral work with S. V. Ley,
University of Cambridge (UK), and G. M.
Whitesides, Harvard University, Cambridge
(USA), he completed his habilitation at the
University of Freiburg in 2002. He then became
associate professor at the University of Dort-
mundand in2004was appointed full Professor
of organic and macromolecular chemistry at
the Freie Universität Berlin. He is recipient of
several awards, including the Heinz-Maier-
Leibnitz Prize of the German Science Founda-
tion (DFG) and a NanoFutur award of the
German Ministry of Science (BMBF). His main
research interests are themimicry of biological
systems by functional dendritic polymers,
with particular focus on applications in nano-
medicine, such as drug, dye, and gene delivery,
as well as regenerative medicine, such as non-
fouling surfaces and matrix materials.
